</s> 278
- 172
patients 82
pts 333
1 172
2 172
3 172
cancer 107
study 457
treatment 287
survival 426
trial 457
4 172
8 122
OS 426
tumor 142
response 255
therapy 287
A 425
CI 389
95% 389
6 172
5 172
disease 82
months 412
30 122
median 25
Cancer 27
clinical 242
We 249
15 146
00 33
In 141
phase 457
analysis 439
PFS 426
HR 389
chemotherapy 164
dose 324
cell 322
45 146
age 492
AM-11 33
P 389
treated 82
10 172
data 9
tumors 361
rate 206
advanced 423
risk 390
received 172
0 172
metastatic 423
primary 206
breast 392
compared 79
prior 92
safety 444
stage 42
expression 316
T 472
cells 322
12 172
grade 271
randomized 457
7 172
Median 25
cohort 68
efficacy 457
progression 426
mutations 7
PM-4 146
PD-L1 73
time 43
This 29
range 25
Center 470
N 78
included 9
II 457
status 141
NSCLC 106
combination 422
activity 207
arm 425
identified 244
enrolled 350
outcomes 249
9 172
including 211
patient 91
Patients 363
weeks 276
I 314
observed 326
11 172
lung 278
based 90
days 276
20 172
mo 101
18 78
Pts 92
0.001 152
2016 350
increased 102
immune 111
m2 276
benefit 287
toxicity 272
surgery 383
assessed 150
inhibitor 469
mutation 52
CT 460
diagnosis 128
samples 96
events 26
B 425
ORR 333
search 126
disclosure 126
list 126
reported 421
performed 96
authors 126
III 457
cycles 276
baseline 138
Visit 126
positive 441
HER2 132
evaluated 233
studies 29
14 172
trials 4
care 219
follow-up 128
PR 366
genes 109
factors 141
Discussion 33
rates 358
CR 366
AEs 26
Phase 457
day 276
IV 42
total 149
16 172
standard 363
DNA 374
24 172
adjuvant 168
cancers 199
21 172
There 82
prognostic 141
women 392
C 425
low 478
13 172
levels 458
endpoint 206
gene 361
testing 10
common 459
Hospital 282
25 172
RT 400
28 172
responses 255
EGFR 278
tissue 22
melanoma 111
17 172
R 177
PD 178
objective 206
L 348
population 181
improved 65
versus 69
SD 366
Medical 470
control 79
test 439
analyzed 305
adverse 26
impact 249
metastases 435
19 172
100 276
carcinoma 199
negative 163
death 398
D 432
PD-1 373
50 25
analyses 439
complete 255
solid 234
60 25
RECIST 150
BC 205
evaluate 249
Of 82
therapies 239
outcome 196
model 439
22 172
cycle 276
pt 82
endpoints 206
50% 456
score 430
ratio 11
2015 105
single 422
recurrence 168
criteria 92
10% 456
40 25
diagnosed 221
ctDNA 225
0.01 152
lower 152
doses 324
Institute 60
receive 363
receiving 41
refractory 368
potential 327
ovarian 382
models 439
cohorts 68
inhibitors 80
However 245
sequencing 109
alterations 237
ongoing 349
receptor 370
increase 326
free 426
plasma 225
radiation 400
defined 90
OR 248
assess 249
evaluable 333
demonstrated 267
poor 416
regression 217
systemic 92
0.0001 313
multiple 331
genomic 374
difference 403
drug 46
ECOG 92
determine 249
BRAF 279
identify 249
molecular 374
For 82
duration 101
blood 473
resection 6
targeted 242
mos 412
differences 249
Among 492
type 194
ER 132
effects 260
confirmed 82
toxicities 26
resistance 278
20% 456
al 105
profile 349
PK 349
recurrent 31
fatigue 26
daily 131
predictive 141
oral 496
colorectal 312
Grade 26
lines 330
progression-free 426
New 230
0.05 403
These 377
65 25
brain 294
CRT 335
report 249
80 25
screening 197
5% 456
Department 282
Primary 206
At 328
characteristics 305
tolerated 324
DFS 307
prostate 0
survivors 263
arms 425
prospective 29
mCRC 312
Cox 217
detected 7
genetic 10
biomarkers 83
Tumor 415
70 25
occurred 421
Discussed 33
relapsed 63
MD 494
collected 83
stable 366
level 325
improve 65
Medicine 107
neoadjuvant 383
MBC 23
eligible 92
MM 331
E 475
26 408
yrs 25
PS 92
31 408
AML 264
23 172
combined 69
placebo 457
Our 377
expansion 234
75 25
limited 245
Displayed 33
antibody 38
week 347
Overall 426
conducted 246
design 324
CA 2
prognosis 416
M 177
29 172
TNBC 80
association 249
pCR 297
CD8 293
Secondary 206
checkpoint 373
specific 238
life 138
weekly 324
burden 159
underwent 59
de 353
Table 98
assessment 90
biomarker 418
regimen 18
role 377
independent 141
addition 65
radiotherapy 400
setting 287
function 336
200 131
NGS 109
partial 366
target 239
hazard 217
35 408
germline 483
27 408
quality 138
incidence 390
escalation 234
secondary 206
metastasis 435
Research 60
size 325
1.1 101
As 350
evaluation 349
CRC 312
pathway 275
mortality 390
health 461
regimens 357
Gy 335
imaging 108
IHC 49
Arm 425
2014 105
diarrhea 26
open-label 457
multicenter 457
completed 16
agents 239
32 408
Oral 33
To 91
first-line 354
KRAS 7
factor 370
NY 230
G 417
nivolumab 418
therapeutic 239
developed 420
change 450
agent 422
National 27
sites 81
yr 24
TP53 7
reduction 347
evidence 377
36 408
achieved 366
liver 251
locally 423
multivariate 217
correlated 211
bone 124
1% 73
protein 361
immunotherapy 373
additional 50
25% 456
Stage 441
2013 105
PSA 479
inhibition 207
antitumor 349
80% 325
York 230
loss 43
review 150
RR 450
relapse 24
biopsy 22
post 59
MTD 324
planned 394
15% 456
scores 138
Health 27
surgical 6
chemo 460
MA 253
history 462
decreased 481
33 464
tested 465
BRCA1 483
monotherapy 80
sarcoma 183
An 487
30% 456
40% 139
HPV 434
pre 473
reached 101
follow 128
effective 420
34 408
cisplatin 35
high-risk 352
tolerability 444
month 481
sample 482
pembro 340
findings 33
exposure 485
AR 486
PM-6 33
administered 432
neutropenia 26
lymphoma 153
initial 222
male 492
100% 328
TX 494
90% 325
determined 90
profiling 374
Treatment 498
reduced 499
neck 434
site 381
NR 51
matched 3
local 381
ALK 106
human 38
predict 115
F 8
AE 26
active 88
subjects 234
induction 63
drugs 46
CNS 319
non-small 470
types 327
nausea 26
experienced 421
squamous 434
clinically 269
required 394
gastric 423
growth 370
After 16
adjusted 217
kinase 469
treatments 287
biopsies 22
paclitaxel 428
0% 478
GBM 437
current 233
support 33
pembrolizumab 340
wks 367
interval 11
42 408
GA 491
worse 39
retrospective 246
approved 4
G3 271
pain 61
normal 44
School 107
2012 105
37 408
method 439
Data 9
FU 443
CTC 362
estimated 439
Group 188
unknown 244
considered 55
somatic 491
mCRPC 479
One 82
recommended 324
39 408
symptoms 61
48 408
promising 422
90 397
Anderson 494
progressive 329
BID 131
13% 456
mL 69
maintenance 70
Texas 494
family 10
features 214
infusion 67
activation 75
stratified 363
Response 366
frequency 78
adults 55
provide 242
47 408
7% 139
38 408
tx 178
head 434
assay 96
measured 473
renal 448
development 239
system 90
enrollment 91
failure 272
61 408
costs 12
6% 139
markers 142
proportion 211
performance 92
Houston 494
nivo 471
64 408
docetaxel 428
Most 492
41 408
23% 456
adenocarcinoma 424
2011 105
0.02 152
43 408
maximum 324
lesions 344
mutant 36
Memorial 230
management 292
circulating 115
33% 456
12% 139
BM 118
met 394
acute 63
8% 139
RCC 448
IPI 308
medical 193
pa 125
panel 10
previous 427
histology 424
sensitivity 129
serum 364
300 131
9% 456
oncology 46
approach 242
55 408
variants 491
node 449
calculated 439
3% 456
statistically 403
designed 457
frequent 273
Boston 253
objectives 206
presence 385
26% 456
controls 147
dosing 324
adult 149
18% 456
MRI 151
17% 456
bevacizumab 447
Cohort 154
platinum 164
AA 479
RAS 157
60% 456
long-term 79
detection 228
intervention 266
QD 496
malignancies 239
Centre 375
anti 373
expressed 166
examined 167
subtypes 214
shorter 152
newly 221
Breast 392
66 408
19% 456
29% 456
11% 456
22% 456
44 408
blockade 373
0.03 152
Cell 386
Bev 181
CTCs 362
selected 149
Here 249
46 408
event 272
decrease 481
subtype 214
favorable 141
central 150
DCR 333
62 408
lymph 449
PIK3CA 433
United 466
Survival 270
highly 113
revealed 468
tients 125
pro 481
improvement 65
subsequent 202
tests 439
16% 139
Further 33
detect 325
56 408
mm 208
distant 307
Sloan 230
majority 211
4% 456
carboplatin 35
validation 235
mut 433
concurrent 216
TKI 106
DLBCL 153
assigned 164
frequently 273
52 408
S 222
compare 79
correlation 297
ng 225
cfDNA 225
CAR 310
With 128
BRCA 414
Kettering 230
63 408
residual 232
v1 150
Part 234
power 325
female 492
myeloma 331
PET 78
targeting 239
table 98
pathways 275
AUC 401
cost 12
repair 315
PC 0
experience 246
colon 323
patterns 248
discontinuation 421
2% 456
V 445
Comprehensive 2
progressed 31
remained 288
DLT 324
RFS 256
established 257
profiles 374
optimal 259
period 260
IC 261
T790M 262
pediatric 183
MDS 264
54 408
14% 139
evaluating 457
42% 456
guidelines 134
database 162
RP2D 234
T-cell 472
remains 245
st 481
consistent 269
150 131
Mean 277
MET 278
From 350
peripheral 473
24% 139
rare 237
confidence 11
2010 117
Kaplan-Meier 217
race 194
aim 420
001 189
elderly 63
France 290
preliminary 349
resected 54
TILs 293
Using 259
pancreatic 486
53 408
leukemia 63
Two 82
responders 255
protocol 90
undergoing 29
35% 456
51 408
68 25
58 408
endocrine 130
31% 139
Patient 158
36% 456
Eligible 92
49 408
starting 324
67 408
anti-tumor 207
FL 153
TC 261
average 265
controlled 457
70% 328
proportional 217
0.04 403
antigen 368
mutational 468
schedule 324
0.1 332
reviewed 117
anemia 26
resistant 497
measurable 92
potent 469
deaths 359
severe 272
67% 456
1.5 332
400 131
PA 336
rash 271
preclinical 207
mutated 7
75% 328
Gr 26
mets 342
O 183
anti-PD-1 472
While 377
selective 469
elevated 452
Study 263
21% 139
44% 456
38% 139
centers 363
variables 439
45% 456
Baseline 305
ET 356
aggressive 302
relative 358
MRD 236
major 360
subset 361
DLTs 324
treatment-related 421
validated 235
expected 365
trastuzumab 130
wk 367
investigated 339
signaling 275
intensity 24
decision 371
PI3K 372
durable 296
cetuximab 144
continuous 324
CP 427
suggests 377
trend 378
0.002 313
59 408
mechanisms 369
28% 139
died 82
Age 39
marker 142
Efficacy 409
HNSCC 434
Other 386
strategies 245
increasing 245
practice 391
subgroup 98
QOL 138
Dose 324
gender 194
safe 422
late 390
volume 398
Clinic 226
Therapeutics 318
55% 456
monoclonal 38
interim 394
treat 487
Safety 444
copy 109
PTEN 433
1.8 332
LEN 87
children 410
Germany 384
excluded 92
IM 413
OC 414
TMB 415
SCLC 180
pathologic 297
selection 418
High 40
It 420
fold 495
56% 328
comparing 79
74 408
NA 348
57 408
predictors 141
untreated 55
Although 377
cm 431
Based 499
log-rank 217
000 351
ıve 294
Care 146
43% 456
subgroups 98
Q3W 131
physical 123
strategy 242
generation 474
heterogeneity 182
stem 63
lack 245
relevant 396
con 446
2.5 332
discontinued 421
27% 139
71 408
BRCA2 483
unresectable 423
surveillance 108
UC 454
formation 33
RNA 96
predicted 299
p-value 313
72 408
relationship 249
01 189
A. 60
completion 16
signature 235
53% 456
Kingdom 466
vomiting 26
distinct 468
gemcitabine 440
initiation 16
ipi 471
result 50
ad 454
RS 168
76 408
logistic 439
120 69
46% 456
comparison 79
EC 480
52% 328
intermediate 352
remain 436
CLL 153
set 235
syndrome 272
continued 304
College 282
47% 139
triple 80
48% 456
multivariable 217
TMZ 437
ipilimumab 308
administration 18
prolonged 426
85% 328
73 441
aimed 420
37% 139
significance 325
options 245
atezo 3
access 160
63% 456
65% 456
39% 456
2.8 332
final 463
Lung 386
induced 322
manageable 334
January 350
suggesting 299
weight 15
key 275
classified 221
AM-12 33
82 408
41% 139
57% 328
parameters 341
tumour 481
58% 328
85 25
provided 50
randomly 363
randomization 16
estimate 439
74% 328
choice 371
PD1 47
demonstrate 29
localized 227
sex 194
NIVO 308
IT 37
tyrosine 469
commonly 273
PARP 315
ratios 11
adequate 92
start 16
program 160
durvalumab 432
GIST 86
PDL1 47
Analysis 305
specimens 49
feasible 50
thrombocytopenia 26
prospectively 480
characterized 237
2004 229
cervical 423
bev 402
Total 57
78 408
500 131
leading 275
0.5 147
TN 60
hormone 130
superior 79
adjusting 194
explored 249
derived 321
mOS 116
increases 267
interaction 70
investigator 150
600 67
cutoff 333
center 363
amplification 372
San 2
PBO 446
insurance 17
fusions 237
orally 496
nodes 449
pathological 297
69 464
organ 92
Day 432
unacceptable 131
On 364
marrow 124
modified 89
AC 165
studied 407
eligibility 92
1.0 332
transplant 24
skin 459
unique 238
TRAEs 421
includes 155
H 388
m² 283
1.4 332
mRNA 316
Tx 103
continue 304
allowed 329
79 408
Metastatic 386
76% 328
platform 474
myeloid 63
microenvironment 322
Italy 224
34% 139
aged 248
hazards 217
1.2 332
retrospectively 117
body 15
ATM 483
IQR 39
MMR 312
HCC 284
FOLFOX 402
lesion 344
future 242
cardiac 272
59% 139
0.003 152
ALT 271
TTP 433
vitro 419
pharmacokinetics 349
infection 133
Updated 409
1000 276
64% 456
54% 456
61% 456
sponse 255
86 408
sig 141
infiltration 142
values 393
77 408
functional 145
glioblastoma 437
Gastrointestinal 451
chronic 148
GI 452
Ib 28
AI 130
invasive 168
83 408
EFS 137
BMI 15
led 421
LDH 452
hospital 158
oxaliplatin 443
knowledge 195
olaparib 346
updated 409
FISH 163
initiated 457
General 253
explore 249
palliative 219
bladder 352
endometrial 480
exon 278
strong 377
Children 263
83% 328
involved 275
recruited 350
moderate 44
Molecular 374
Prior 92
recommendations 13
2.6 332
appears 65
p16 465
fusion 237
anti-PD1 472
targets 239
populations 44
NC 2
72% 328
detectable 170
84% 328
taxane 357
reports 354
epithelial 382
univariate 217
LN 132
WT 157
activated 322
rectal 54
mechanism 369
pathogenic 491
62% 456
1.9 332
68% 328
fraction 182
comparable 444
location 323
66% 456
95 208
78% 328
71% 456
series 468
California 2
curative 339
esophageal 423
BEV 437
irinotecan 216
PCa 0
benefits 65
variant 491
count 473
0.005 152
malignant 120
peritoneal 382
sorafenib 284
Between 350
Rochester 226
enhanced 322
nodal 209
77% 456
examine 249
smoking 492
white 194
institution 117
mPFS 116
TCGA 235
CSF 362
clonal 182
individual 285
financial 461
CD3 293
2.0 332
32% 456
inclusion 92
87 408
tool 195
1.7 332
investigate 249
88% 328
FOLFIRI 402
global 210
soft 183
T-DM1 130
Mayo 226
percentage 211
Preliminary 314
ITT 256
associations 249
cytotoxic 322
contrast 151
predictor 141
reductions 269
hematologic 77
M. 470
82% 328
ability 213
ALL 63
GC 267
accrual 394
sided 325
extracted 96
cumulative 390
participants 161
73% 328
resectable 423
prevalence 97
warranted 33
0.3 332
load 468
MYC 62
regions 109
rituximab 281
MSI-H 312
diagnostic 292
1.6 332
sought 155
actionable 374
physician 487
49% 456
lymphocytes 293
FDA 4
NCI 453
decisions 292
2.4 332
alive 128
QoL 138
antibodies 373
scans 317
distress 61
NHL 153
ES 110
Science 146
develop 302
2008 105
reduce 484
routine 292
Dana-Farber 253
Adjuvant 168
select 308
ve 371
survey 461
staining 49
larger 33
AST 271
NE 178
methylation 437
MSI 312
CC 323
88 408
involvement 319
800 67
expressing 321
MEK 184
DOR 101
spectively 456
79% 328
Both 190
independently 141
69% 328
confirm 33
92 127
PO 131
1.3 332
2.3 332
adherence 197
2006 162
absence 294
81 408
exploratory 409
vivo 419
chemoradiation 335
monitoring 228
84 408
limiting 324
thyroid 199
Women 392
Angeles 2
double-blind 457
0.004 152
acceptable 422
consecutive 117
2.1 332
gastrointestinal 459
ADT 0
term 354
androgen 497
remission 77
pretreated 357
Adverse 192
Only 82
2000 162
Association 185
CTCAE 192
Despite 245
NCDB 229
classification 365
measures 210
CD4 293
enzalutamide 479
KIT 86
stages 229
hypothesized 245
definitive 54
hypothesis 325
51% 456
LR 289
Medicare 274
characterize 249
96 127
improves 65
NACT 383
3.0 332
NK 322
depression 61
dependent 165
vascular 112
Y 348
Nivo 340
0.2 332
education 461
Early 366
240 131
heavily 357
89 408
89% 328
HER2-positive 130
2009 105
99 397
Los 2
TIL 293
immunohistochemistry 49
250 131
statistical 200
prediction 209
critical 404
81% 328
records 162
3.5 332
2.7 332
02 189
unclear 420
feasibility 29
5.5 379
4.0 332
SOC 346
chemoradiotherapy 335
STS 110
driver 237
94 408
label 457
Three 82
conventional 65
damage 315
DDR 257
approval 4
D1 276
Blood 188
second-line 354
allele 433
alteration 237
NCCN 134
PN 431
dexamethasone 87
SCCHN 434
HNC 434
class 5
identification 474
biological 396
ON 375
failed 330
sensitive 315
FGFR 370
alternative 29
variable 430
hypertension 271
undergo 59
Key 92
platinum-based 164
Oncol 105
PALB2 483
Developmental 318
MSS 240
lenalidomide 87
J. 107
individuals 133
System 455
pression 316
disease-free 307
che 164
linked 221
160 454
Inc 53
Database 229
registry 162
0.6 332
2.2 332
odds 17
Mb 415
glioma 301
TKIs 106
osimertinib 278
autologous 436
mRCC 448
NLR 364
biology 196
en 475
prevention 476
0.4 332
S. 470
option 88
comprehensive 374
linear 439
atezolizumab 340
assessments 150
cyclophosphamide 67
Score 168
87% 328
treating 487
London 466
Risk 40
125 318
Compared 17
0.7 332
93 408
Enrollment 394
encouraging 28
metabolic 299
dose-escalation 234
CS 161
IO 499
CRPC 479
avelumab 340
CVD 102
ibrutinib 19
molecule 467
binding 38
randomised 457
courses 18
Netherlands 256
margin 209
population-based 162
Multivariate 217
Division 470
oncologists 13
screened 175
histologic 214
salvage 281
Leukemia 171
CRS 310
proliferation 322
training 235
implications 21
exome 109
investigation 33
q3w 432
published 246
minimal 65
applied 235
capecitabine 428
OH 226
suggested 205
Tumors 455
utility 292
gression 481
Furthermore 267
alpha 325
tolerable 422
mTOR 372
concentrations 458
carcinomas 199
GPS 40
coverage 274
Q2W 42
MGMT 437
LM 47
GEP 240
half 13
mAb 38
92% 328
SEER 114
enhance 238
receipt 194
proteins 275
5.6 379
absolute 217
K 55
correlates 280
ABC 306
PCR 83
post-treatment 142
Asian 174
Ph 413
radiographic 14
Malignancies 171
RRMM 87
earlier 65
understanding 74
93% 328
subsets 142
Additional 249
histologically 462
NAC 383
tissues 301
86% 328
concordance 182
Disease 188
combinations 422
methods 285
scan 317
ment 79
instability 312
GEJ 81
serous 414
wild-type 7
CDKN2A 273
S-1 85
imatinib 86
ion 176
Toronto 375
short 79
pathology 90
probability 285
immune-related 421
DC 93
C. 60
Sciences 282
FFPE 96
remaining 222
Prognostic 388
comorbidity 194
counseling 10
Quality 146
St 263
enriched 299
conditions 148
males 490
CheckMate 340
B-cell 153
define 327
entire 430
healthcare 274
childhood 263
complications 359
community 160
se 83
Genomic 374
flow 473
urothelial 340
ing 176
decline 14
isolated 399
0.84 389
preoperative 335
carriers 483
dis 82
paired 142
Hematologic 171
HLA 316
percent 128
Prostate 0
CTLA-4 373
Genitourinary 122
acid 203
comorbidities 194
If 134
substantial 245
When 1
0.70 389
letrozole 130
Five 82
terms 79
achieve 436
Cleveland 226
December 350
4.4 332
91 408
Impact 146
0.8 147
visits 148
180 149
ERBB2 279
mice 495
complex 190
RCT 29
MPM 120
Given 245
genome 109
symptom 159
demographic 194
Jan 350
109 338
reference 351
intervals 11
rank 439
motherapy 164
infiltrating 293
distribution 303
3.9 379
medication 158
J 105
3.7 332
mu 7
Plasma 83
HRQoL 138
SNPs 402
anxiety 61
Nivolumab 340
abiraterone 479
dMMR 312
expanded 310
B. 115
delivery 238
countries 274
pooled 9
activating 278
utilization 74
pre-treatment 22
2007 105
98 408
03 189
lead 413
responded 82
6.5 379
EORTC 138
influence 249
estimates 289
supporting 326
6.1 379
ligand 373
predicting 145
Spain 253
0.51 389
Cancers 386
Assessment 295
gain 190
occur 237
gov 453
sunitinib 448
CAR-T 310
ACT 54
CRF 203
diseases 390
achieving 236
Approximately 164
0.007 152
acquired 278
log 439
doxorubicin 309
0.008 152
largest 74
bid 131
0.9 332
4.6 379
fulvestrant 130
Massachusetts 253
observation 358
main 287
vaccine 238
RB1 7
RP 0
E. 470
documented 92
Immunotherapy 318
Dec 350
dose-limiting 324
0.75 389
4.1 379
dual 207
malignancy 227
Common 192
schedules 324
guide 292
multi-center 457
4.7 332
2.9 332
uptake 317
extent 392
asymptomatic 247
black 194
inhibits 275
plan 265
hepatic 251
metformin 252
CGP 374
represents 245
TCR 316
sarcomas 110
consolidation 335
LV 443
CMS 259
AZA 264
IL 107
true 344
Simon 325
international 487
assays 96
106 338
extended 267
stratification 141
trends 74
reporting 46
IB 441
colitis 421
characterization 374
Francisco 2
3.6 332
enroll 324
hereditary 21
pilot 29
Colorectal 451
non-responders 255
CRi 236
SCC 434
Non-Small 386
HSCT 99
Philadelphia 2
providing 242
reasons 213
evolution 182
physicians 461
MN 226
assessing 29
respond 80
cytometry 473
Immune 113
Trial 453
sequential 283
0.69 389
Surgery 282
dysfunction 61
Therefore 420
margins 168
developing 390
presentation 75
0.06 403
positivity 73
Ki67 132
di 117
Outcomes 115
novo 353
radical 222
irAE 421
correlate 299
Circulating 115
Med 94
APC 483
cognitive 123
c-Met 106
SS 110
utilized 439
programmed 373
ADC 166
neuropathy 271
0.64 389
apoptosis 419
0.85 389
0.66 389
minimum 16
LS 187
error 325
inferior 62
cut-off 350
mixed 285
Eligibility 92
synergistic 207
fractions 335
Days 432
clearance 268
Hispanic 201
Melanoma 397
Trials 453
VEGF 112
approaches 242
driven 207
7.5 379
More 80
6.0 379
4.3 332
0.93 389
Following 59
candidates 141
febrile 26
Drug 4
SAEs 26
Higher 152
matching 265
blinded 150
exercise 266
5.3 379
dissection 449
8.3 379
3.1 332
threshold 200
academic 363
density 293
mass 268
pattern 385
symptomatic 14
next-generation 109
harboring 278
NF1 493
single-arm 457
Oct 350
injection 347
liquid 374
Network 375
indications 213
temozolomide 437
high-grade 468
NRAS 7
erlotinib 278
ML 257
HIPEC 383
transplantation 99
NB 416
Gleason 431
David 470
domain 361
105 408
IDO1 32
pneumonitis 421
ob 260
balanced 305
serial 83
abnormalities 272
reaction 271
neo 130
GS 431
CDK4 130
scale 210
directed 242
97 408
0.77 389
0.99 135
morbidity 159
accuracy 209
specificity 129
hours 300
finding 80
registered 9
integrated 257
Exploratory 206
withdrawal 16
signals 334
ESR1 433
Epidemiology 114
3.3 332
meaningful 417
phenotype 241
mths 379
R0 383
irAEs 421
pazopanib 183
NPC 423
triple-negative 132
Stanford 2
contribute 369
field 400
prednisone 479
96% 328
101 455
L. 115
autoimmune 272
rapid 44
regulatory 5
archival 83
5.1 379
108 318
Low 40
0.81 389
Final 409
postmenopausal 130
112 165
0.67 389
0.57 389
Cb 445
aberrations 237
affect 65
risks 289
stromal 256
females 490
cancer-related 156
diabetes 452
Fisher 439
visceral 306
MAPK 372
Best 366
qd 131
suppression 322
oncogenic 237
V600E 279
blocks 38
visit 219
Chinese 282
CHEK2 483
PDAC 440
HIV 359
supportive 219
IMRT 335
FDG 317
PAZ 499
Survivor 263
H. 60
cellular 238
precision 242
3.2 332
high-dose 18
goal 74
excellent 245
exact 439
Four 82
effector 32
5.4 379
modeling 285
clinic 219
left 485
double 457
0.52 389
0.53 389
0.73 389
Six 82
IR 467
8.5 379
0.63 389
Kaplan 439
0.55 389
portion 324
consent 16
literature 246
C1 276
5.8 379
FGFR3 433
ethnicity 194
SC 309
cutaneous 308
U.S. 4
XRT 121
PM-2 146
During 8
Michael 107
personal 10
mBC 130
Symposium 146
102 291
referral 219
ic 176
started 16
Hazard 11
0.68 389
experimental 428
signatures 361
mastectomy 449
110 429
address 461
0.61 389
Europe 81
Chemotherapy 168
Radiation 384
118 429
placebo-controlled 457
0.62 389
inform 154
combining 373
immunity 322
City 53
3.8 332
disparities 74
RCTs 37
region 213
national 162
0.59 389
personalized 242
shared 182
X 96
measure 46
Clin 105
ESMO 46
Royal 466
CEA 334
0.009 152
limit 268
peptide 311
smokers 492
PV 483
Central 455
gliomas 301
afatinib 278
hospitalization 158
crizotinib 58
clones 299
trametinib 184
osteosarcoma 110
MEL 308
ASCT 331
medicine 242
process 195
healthy 258
P. 378
rationale 207
103 408
PEM 304
Margaret 375
heterogeneous 302
0.71 389
estrogen 130
Pembro 75
landscape 374
min 300
97% 328
0.58 389
nab-paclitaxel 440
November 350
identifying 374
BL 170
NS 84
accrued 325
early-stage 292
Meier 439
likelihood 388
divided 430
systematic 246
persistent 91
0.65 389
NET 159
progressing 477
progress 245
wild 402
underlying 97
represent 245
L1 373
intravenous 432
G2 271
unselected 80
p53 241
anti-cancer 104
quantitative 49
onset 99
castration-resistant 479
diffuse 153
robust 249
Ewing 110
vemurafenib 184
mediated 322
neuroendocrine 199
etoposide 35
AYA 183
AM0010 472
SBRT 400
GCT 227
DT 119
MI 107
staging 209
Evaluation 455
well-tolerated 334
91% 328
0.83 389
anthracycline 18
covariates 217
candidate 369
0.48 215
0.79 389
excluding 20
0.08 403
dx 133
histological 424
1.04 135
Services 146
4.2 332
fewer 449
0.87 389
Objective 366
length 159
inflammation 473
4.9 332
Rx 247
4.5 332
Lancet 105
longitudinal 298
responding 255
107 338
elevation 271
0.006 152
HGSOC 414
LOH 414
receptors 112
SCT 24
ccRCC 316
mts 157
HCT 24
interventions 461
reducing 65
Princess 375
occurring 271
ac 176
July 350
Neoadjuvant 165
T2 395
0.44 389
stopped 394
0.07 403
Multivariable 217
1.03 135
recorded 398
controlling 194
racial 74
postoperative 383
March 350
Time 270
ranging 276
IIIA 181
indicating 393
stress 61
degree 182
signs 28
6.3 379
grades 271
mouse 419
ranged 179
initially 16
providers 461
ROS1 106
T-cells 322
rearrangements 237
Mutation 415
5.2 379
outpatient 219
WHO 424
Ab 32
intent 339
MF 77
TML 343
Gynecologic 146
real 287
component 369
Registry 162
diverse 205
IgG1 38
Preclinical 207
conjugate 309
1.00 389
signal 112
141 354
domized 58
tumours 466
0.97 389
counts 473
improving 65
meta-analysis 246
7.3 379
Yes 348
5.7 379
categorized 221
ive 176
6.2 379
effectiveness 12
ra 94
concomitant 335
TR 119
0.78 389
0.39 215
altered 7
CBR 366
mild 459
State 233
network 257
delivered 266
PD-L2 73
amplifications 237
agreement 393
allogeneic 24
Class 240
Head 434
require 245
proven 462
Ann 107
demonstrates 207
improvements 65
Pt 305
Foundation 466
0.86 389
regional 449
0.49 389
0.29 389
upfront 287
116 291
recovery 77
centrally 187
9.4 379
recruitment 394
variation 97
electronic 162
Any 348
MC 262
palbociclib 130
dosed 67
single-agent 409
everolimus 448
monthly 59
suppressor 369
release 310
invasion 385
lymphocyte 473
Responses 101
cytokine 310
delayed 41
BRAFi 190
bx 142
muscle 203
RC 54
pleural 120
LAN 355
MCL 153
4.8 332
leads 245
categories 356
Experimental 318
pharmacokinetic 349
0.56 389
0.82 389
0.13 215
cluding 233
T1 34
130 429
I-III 244
Recent 377
predicts 141
Univariate 217
purpose 155
asso 152
extensive 180
fixed 22
sequenced 415
Type 386
EVE 448
CN 106
Hematology 470
Cmax 179
TEAEs 26
AJCC 54
7.0 379
sufficient 22
neoantigen 111
mismatch 312
Neck 434
vaccination 311
cytotoxicity 322
anti-EGFR 144
Noncolorectal 122
Biology 185
intensive 63
7.8 379
algorithm 235
immunogenicity 444
mUC 340
1200 276
Combination 80
0.88 389
continues 394
94% 328
luminal 132
exhibited 179
0.72 389
0.89 389
0.91 389
117 451
119 291
N0 431
Randomized 457
124 338
understand 74
Scale 295
multi 486
med 236
1.02 135
128 451
7.4 379
deficiency 315
adjustment 141
1.05 135
Future 74
core 22
By 323
2005 105
Since 9
8.2 379
SLN 209
African 174
SM 227
generated 265
historical 358
random 9
xenograft 419
capture 474
ClinicalTrials 453
OOP 274
intratumoral 472
lasting 366
UK 466
underway 33
natural 238
induce 322
U 100
targetable 237
Lee 60
PARPi 315
European 375
origin 376
AS 0
hospice 17
CO 447
BSC 116
drug-related 271
Paris 290
debulking 383
CCI 194
Cet 402
pemetrexed 35
CD30 387
wt 7
ND 20
VTE 390
FLT3 236
concerns 461
geriatric 123
settings 160
recurrences 137
social 123
Targeted 374
8.4 412
le 176
respect 358
1.09 135
fluorouracil 283
1500 432
0.41 215
locoregional 168
0.94 389
parallel 324
institutions 429
135 318
0.10 403
0.40 389
poorer 141
140 204
creased 102
users 465
communication 461
dyspnea 272
action 334
sociated 262
analyze 249
Subjects 59
establish 349
base 109
7.1 379
drivers 237
basis 391
consisted 42
adaptive 238
spending 274
PAL 306
0.50 389
D. 60
9.5 379
laboratory 233
deletion 237
Gene 316
February 350
RET 370
implementation 193
hepatitis 421
blasts 236
Thoracic 386
microsatellite 312
thoracic 54
DM 381
N3 333
CD19 310
CML 413
7.2 379
accurate 195
Gustave 290
Roussy 290
enrolling 453
vanced 454
Local 383
dif 196
aims 327
1.07 135
0.1% 489
142 451
0.76 389
138 286
175 401
lacking 205
CDK 130
referred 219
lowest 258
182 451
143 451
hospitals 219
1.01 135
subsequently 59
gem 440
Washington 72
9.3 379
LET 446
States 466
8.1 379
neutrophil 300
Pharmacology 318
bias 37
anticancer 239
income 194
infections 359
satisfaction 138
psychological 123
IDH1 241
CM 240
promoter 437
SIR 121
mM 419
pulmonary 459
cytokines 473
REG 231
clonality 255
dabrafenib 184
GEM 440
CINV 41
L858R 223
Sarcoma 183
Pediatric 263
behavior 123
varied 201
utilizing 474
direct 5
cluded 82
quantified 320
anorexia 26
06 189
Alliance 72
comparisons 307
JCO 105
Pembrolizumab 340
superiority 325
0.34 389
September 350
0.35 215
114 451
deemed 360
2003 117
G. 475
They 363
0.92 389
0.38 389
0.46 389
129 451
99% 328
131 318
validate 292
hormonal 479
demographics 305
0.96 389
Effect 33
unrelated 272
one-sided 325
0001 403
curve 430
scored 49
maintained 138
IIIB 42
delay 119
DMFS 307
inflammatory 339
ribociclib 130
8.6 51
QLQ-C30 138
Progression 270
nificantly 152
abi 479
pharmacodynamic 349
3.4 332
Bevacizumab 52
Genetic 53
0.25 403
ENZA 479
dataset 235
WA 72
tox 271
processes 213
first-in-human 234
mesothelioma 120
CCL5 402
follicular 153
successful 391
focused 160
overcome 245
Development 466
Carolina 2
modest 245
severity 192
Complete 366
iv 176
0.74 389
correlative 206
Bayesian 285
requiring 294
ineligible 92
monitored 16
NCT 79
White 174
individualized 363
unmet 245
Thus 249
curves 217
0.025 403
10.3 379
nificant 141
Index 392
Average 247
October 350
differed 194
requires 90
provider 461
transcription 275
9.7 379
177 477
exposed 220
C2 276
reversible 272
v4 192
Robert 107
concentration 458
memory 203
Institut 290
polymorphisms 402
HGF 207
pancreas 199
self-reported 123
panels 10
minutes 266
EOC 382
215 451
peptides 311
SA 144
NY-ESO-1 321
CD73 47
cluster 316
laparoscopic 137
IP 428
HMA 264
kinases 469
challenge 245
decision-making 195
Prospective 292
International 188
7.9 379
12.5 379
104 45
Daniel 107
EBC 130
TTR 307
0.98 389
meet 133
avoid 209
upper 251
0.43 215
115 451
0.90 389
Seoul 282
SWOG 453
0.36 215
Pittsburgh 60
134 286
0.12 403
detailed 196
10.9 412
9.6 412
Toxicity 192
involving 237
surrogate 37
Factors 71
0.37 389
gr 421
homologous 315
institutional 246
offered 156
observational 476
Criteria 192
steroids 272
P-value 313
MS 81
2002 162
FDG-PET 108
232 171
reactions 26
induces 322
HRD 315
ATC 273
Incidence 390
VUS 201
planning 461
reveal 374
framework 46
Seattle 72
11.7 412
Shanghai 282
hematological 459
Lymphoma 171
TME 297
DLL3 180
LCNEC 181
RMS 183
HL 153
LARC 335
post-operative 435
MT 214
CCRT 335
TPS 73
Informatics 146
karyotype 64
SMM 331
investigational 38
inhibitory 322
cure 195
nervous 319
era 196
Program 27
edition 463
Villejuif 290
HER2-negative 130
deleterious 483
fever 272
agonist 38
PRs 333
T. 205
0.80 389
Within 398
Nov 350
bilateral 319
activities 266
0.19 403
allowing 238
AKT 372
126 303
0.95 389
0.33 389
0.45 389
ALND 449
Tissue 22
continuously 131
98% 328
Outcome 295
changed 211
account 285
Number 491
variability 285
N. 107
endothelial 112
timing 158
Rb 132
1.13 135
enrichment 316
digital 83
abdominal 459
top 235
first-in-class 469
macrophages 293
triplet 496
Prevention 197
intake 258
mammography 395
resource 160
Additionally 66
cytogenetic 64
barriers 461
De 169
6.8 379
tube 382
pretreatment 142
KPS 250
Stable 366
PI 252
VGPR 411
hematopoietic 63
ICOS 472
CTX 184
NETs 355
ACP 461
DRd 411
Rd 411
Skin 397
tools 195
success 242
French 290
Global 295
IN 384
project 160
ith 176
IRB 117
Therapy 270
families 10
B-ALL 296
warrant 33
lipase 271
G4 271
escalating 496
attributed 271
8.0 379
6.4 379
Long-term 354
context 242
nucleotide 109
repeated 90
Ratio 270
0.47 389
0.22 403
exists 302
aromatase 130
DCIS 289
0.60 389
irrespective 141
121 3
VA 2
po 176
Support 140
FGFR2 273
10.2 412
deterioration 138
10.6 379
0.015 152
heart 102
5.0 379
146 204
vitamin 476
separately 285
offer 242
tween 258
nomogram 209
Expression 293
express 321
Out 305
chest 460
9.1 51
James 470
created 265
subject 82
switch 119
ULN 355
11.2 379
reflect 182
claims 162
overexpression 275
9.2 379
form 155
mucositis 26
appetite 271
databases 162
nationwide 156
neurotoxicity 310
DL 324
formed 96
restricted 34
recombination 315
graded 192
Treg 32
discovery 345
R. 60
medications 247
diagnoses 490
CRP 364
AZD1775 496
Vd 411
NOS 406
lymphomas 153
impairment 123
cholangiocarcinoma 199
NTX 310
ESCC 423
nab-P 440
cabo 448
PSADT 0
Sx 6
ACA 274
R-CHOP 281
HDI 471
MBM 103
broad 330
pivotal 58
unexpected 334
focus 155
Finally 299
Chapel 2
Hill 2
deprivation 497
difficult 155
11.1 412
360 429
humanized 38
Nashville 60
epidermal 370
Current 302
unconfirmed 333
6.9 51
1.06 135
Amsterdam 470
surgeons 449
proposed 377
landmark 426
0.54 389
Pre 178
August 350
0.013 313
187 451
Thomas 470
0.11 403
0.15 403
0.28 389
M0 54
biologic 141
cardiovascular 390
Seven 82
multigene 10
exist 155
IA 181
Charlson 194
accurately 195
Adjusted 11
statistics 439
angiogenesis 112
radiological 344
annual 490
run-in 324
shrinkage 481
fo 176
Marsden 466
amp 278
Mutations 7
7.6 412
375 283
confer 410
BCL2 62
molecules 5
directly 238
public 274
depth 415
Advanced 416
deficient 312
Cy 67
W 197
discussions 461
neoplasms 390
albumin 364
junction 423
tremelimumab 432
vismodegib 131
PEMBRO 178
Small 386
mi 73
DEX 87
SP 39
EBRT 431
MSK-IMPACT 109
AR-V7 479
OPC 222
services 461
chimeric 368
summarized 101
accumulation 495
defects 315
standardized 265
12.7 379
6.7 379
binds 38
pharmacodynamics 349
ef 29
German 384
evaluates 457
regulation 275
LVEF 247
gBRCA 414
Main 81
05 189
123 451
0.20 215
201 451
0.42 389
0.011 313
record 162
132 418
computed 108
real-world 4
144 45
Correlative 349
1.11 135
ages 221
participating 161
165 451
PDX 419
Neutropenia 26
sum 344
demonstrating 296
sponses 296
frequencies 7
dynamics 83
del 475
questionnaires 138
selectively 275
determination 90
Bone 250
13.6 412
harbored 491
Fatigue 295
WES 109
differentiation 275
Black 174
Atlanta 253
SNP 97
Genetics 197
MLH1 483
GT 10
screen 97
typically 245
syndromes 21
technology 160
external 400
escalated 324
NTRK 237
EGFR-mutant 278
CF 137
edema 459
adenocarcinomas 199
hepatocellular 314
caregivers 461
PSMA 477
doublet 164
PBMC 473
deep 310
bendamustine 153
mFOLFOX6 423
BV 402
PRRT 355
cost-effectiveness 12
BCG 352
enza 479
Chronic 171
payments 46
Medicaid 17
MTX 18
ibr 19
KRd 411
serve 374
host 238
multi-institutional 246
137 318
prevalent 102
decreases 65
te 94
pre-treated 28
Regional 383
futility 394
0.5% 489
non-inferiority 358
bio 437
0.31 389
Similar 403
John 107
0.23 215
Cycle 432
113 291
8.8 379
T3 20
ductal 199
prevent 29
0.18 403
emotional 123
fit 155
play 369
Duke 2
recommend 134
submitted 4
es 234
1.4% 489
preferences 461
7.7 379
Western 226
carried 156
ROC 430
separate 486
resolved 272
Columbia 230
Partial 366
collection 391
sleep 61
Cambridge 466
adding 287
investigator-assessed 206
Brain 188
d1 283
tions 97
variety 242
Surveillance 114
End 114
Single 71
epigenetic 241
13.8 412
st-line 371
Rate 366
11.9 412
prescribed 41
TT 247
TS 23
constipation 26
PG 401
AL 55
napabucasin 28
inhibit 207
Each 59
incurable 88
comprised 89
HD 337
gut 111
Hereditary 197
vaginal 266
AF 433
247 286
melanomas 56
BRAFV600E 103
code 158
codes 162
Hopkins 0
hour 216
hypoxia 34
Baltimore 470
QW 276
inpatient 158
IL-2 321
combo 144
145 318
EZH2 241
neuroblastoma 183
antigens 299
CD38 331
repertoire 113
IMiD 87
bortezomib 87
ETS 116
BTC 423
EBV 434
SUN 499
CABA 167
InO 24
DVd 411
implicated 275
production 322
Over 490
emerging 239
quencing 83
produced 322
pyrexia 26
1.25 135
supports 377
tu 94
ia 176
sequence 83
1.08 135
intermittent 324
1.19 135
Control 366
incomplete 77
questionnaire 138
111 45
Analyses 192
04 189
Unit 466
171 145
Kim 384
stroma 293
369 218
x2 149
compliance 266
213 218
Subgroup 358
situ 49
insufficient 154
uncommon 237
195 451
ethnic 74
nuclear 275
153 318
fatal 272
sur 161
9.9 379
167 451
168 218
missing 303
existing 245
two-stage 325
private 17
neo-adjuvant 6
pairs 182
Comparison 455
Multiple 71
Republic 282
facility 194
array 96
ica 176
tations 7
rearrangement 106
Changes 15
modality 6
April 350
disorders 272
5.9 379
11.0 412
Interestingly 7
correlations 341
lymphopenia 26
10.7 412
Increased 102
enzyme 275
203 451
TE 411
270 455
CD20 62
tolerance 216
Beijing 282
rapidly 44
DUR 432
indication 50
usual 266
Participants 266
abnormal 272
relatives 10
ciated 152
autophagy 419
BRAFV600 184
Up 496
incremental 12
suitable 435
crossover 426
regorafenib 231
VOD 99
concern 213
ligands 112
synovial 110
kidney 459
oropharyngeal 434
STAT3 32
neoantigens 111
survivorship 461
pomalidomide 87
naive 340
LAP 223
gastrectomy 137
hospitalizations 158
Nonprostate 122
HDCT 227
NEPC 180
ED 180
ALC 58
DARA 87
Dex 87
gefitinib 278
sustained 296
aging 155
Hodgkin 153
pertuzumab 130
living 44
patient-reported 298
Daily 463
ap 213
Statistical 407
Biomarker 418
availability 213
Initial 314
safely 247
Yale 113
Treatment-related 421
Sarah 60
efficient 242
IRCCS 224
198 429
recurrence-free 256
SAE 272
Genome 415
analysed 83
favor 402
uncertain 491
supported 140
1.27 135
0.26 215
0.27 389
Asia 81
Those 395
0.21 403
350 429
1.12 135
Also 211
10.0 379
11.3 412
content 203
0.0005 313
anaplastic 378
F. 107
2.5% 173
139 204
310 286
SE 403
Predictive 388
151 318
1.18 135
Little 74
toxic 296
accelerated 324
equally 358
205 286
170 451
impacts 196
172 451
anti-PD-L1 373
BCR 0
consists 149
polymerase 315
abemaciclib 8
10.8 412
frontline 63
TNBCs 293
neurologic 272
multiplex 96
cross 31
Maria 169
plans 274
domains 210
prophylactic 484
Differences 200
differential 468
worsening 260
update 409
kinetics 205
upregulation 32
translational 453
displayed 299
Significant 203
infiltrate 297
composition 111
surface 321
Currently 302
MSH6 483
committee 9
10.5 379
Ten 82
0.017 152
LC 381
differentiated 199
deletions 109
mental 148
ICER 12
HG 241
Correlation 45
RT-PCR 49
AMG 496
occurrence 272
Improved 138
ONC201 467
Johns 0
Cisplatin 336
Flu 337
conditioning 57
cavity 20
virus 56
sidedness 402
GU 492
sarcomatoid 424
rPFS 479
ENZ 479
AD 220
MFS 430
myelodysplastic 64
DOX 425
oropharynx 434
OPSCC 434
CAV 46
CPCs 331
ILD 354
aPD1 421
clinicians 160
molecularly 242
extension 380
components 369
emerged 360
promise 245
anti-HER2 130
original 468
genomics 242
transcriptome 96
0.2% 489
tion 65
procedure 435
surveyed 461
declined 303
0.32 215
0.16 215
162 429
apparent 344
Istituto 224
advantage 205
Standard 164
C3 387
0.014 313
N1 20
1.14 135
10.1 412
histologies 199
I. 60
opportunity 287
Unknown 270
periods 490
BCI 388
Notably 361
166 397
participation 487
Positive 303
spective 363
version 192
currence 431
228 451
Validation 397
yield 10
dynamic 374
Comparing 79
monocytes 322
Several 302
employed 407
11.5 379
HT 252
6.6 379
BCBM 132
INV 150
intracranial 294
sampling 59
cis 187
undetectable 170
lost 43
ICI 100
ARID1A 273
harbor 237
Her2 132
0.17 403
pg 458
2001 117
Major 446
antagonist 497
stemness 28
recurred 380
gained 12
Tregs 297
CD68 293
cabazitaxel 479
implemented 265
USA 4
Illumina 96
chain 339
minor 13
Somatic 415
survived 128
viable 436
IDH 301
bowel 459
MVA 84
tumor-infiltrating 73
non-squamous 424
cytogenetics 64
leucovorin 283
non-Hodgkin 153
GPC3 440
CCS 263
left-sided 323
mt 343
pelvic 335
mIDH1 241
CAB 379
prostatectomy 0
CRx 6
nasopharyngeal 423
price 46
RUX 77
Ibr 19
BRG 58
nail 41
event-free 206
Many 461
spectrum 182
supplement 463
acetate 479
Retrospective 246
relevance 249
informed 265
identifies 374
peak 310
necrosis 297
sepsis 272
observations 327
on-treatment 473
Human 462
ana 475
rs 94
Arms 425
420 19
0.30 389
Surgical 384
interactions 396
246 204
238 218
completely 435
1.20 135
Agency 4
allocated 164
q1w 401
appeared 334
158 397
category 194
147 318
measurements 317
experiencing 248
None 438
218 451
1.41 135
mul 486
13.9 412
quartiles 430
criterion 81
Durham 2
sTILs 132
Wang 282
increasingly 245
Israel 4
clinicopathologic 244
Male 492
DR 281
8.9 277
Odds 11
competing 398
Japanese 8
coding 109
Park 107
Rates 173
managed 248
optimize 155
oncologist 13
LE 137
tomography 108
fluorescence 22
predisposition 21
relapse-free 256
0.0002 313
leukopenia 26
software 265
189 204
prophylaxis 19
inoperable 423
controversial 244
ceived 18
concordant 182
Moreover 182
hyperglycemia 271
represented 279
pending 394
bispecific 38
DFI 356
231 286
Pain 14
LY 349
Wilcoxon 439
VAF 170
Use 218
cell-free 374
HS 461
RB 319
Sydney 375
rucaparib 164
Symptom 295
Durvalumab 38
nM 419
uterine 199
Adult 336
injury 459
GM-CSF 352
mcg 276
Due 302
evaluations 349
low-grade 301
methotrexate 18
Bethesda 27
PCNSL 319
max 26
NT 66
Activity 183
VEGFR 370
immunomodulatory 239
axis 373
attributable 148
R1 297
Rova-T 180
XELOX 428
FT 210
MSKCC 244
relapses 24
borderline 335
stay 159
neg 387
exclusion 92
stopping 394
perioperative 354
cisplatin-based 335
HTN 272
PF 335
QALY 12
revGA 414
CIS 352
classifier 235
BAT 14
BRCAm 414
gp 6
Cost 12
EOL 461
BR 281
MMB 77
ponatinib 254
SOS 99
TRT 100
Jude 263
tract 459
mucosal 459
hrs 67
essential 396
geographic 194
text 463
printed 463
209 204
13.3 412
Sequencing 474
Peter 107
Haven 113
TRAE 421
Peripheral 473
antibody-drug 309
Au 94
9.8 412
served 260
Recurrence 168
0.4% 489
undergone 117
0.14 215
1.35 135
256 218
axillary 209
152 127
Heidelberg 384
prespecified 394
169 451
preference 461
calculate 439
1.33 135
0.09 403
married 194
low-risk 352
12.9 412
425 397
0.016 152
1.16 135
clinicopathological 141
team 160
amplified 163
Similarly 215
188 451
Events 192
Dx 147
systems 238
190 45
156 451
155 291
board 193
hypothesize 249
reverse 96
unit 219
Harvard 253
myelosuppression 26
lymphocytic 63
12.5% 223
registration 9
assuming 325
RTOG 79
radiologic 150
microarray 96
Feb 350
K. 107
rechallenge 167
applications 4
Brazil 169
Functional 295
ANC 300
Belgium 169
synchronous 256
320 218
Whole 122
located 323
Memphis 263
Cornell 230
33.3% 48
tumoral 142
Samples 96
offers 242
IFN 413
450 441
simultaneous 374
confirmation 380
inherited 21
Life 295
MSH2 483
Lynch 483
Caucasian 492
multi-gene 10
Eight 82
FH 491
familial 21
207 451
AJ 10
BTK 469
papillary 199
two-sided 325
practices 160
multidisciplinary 160
FC 316
239 122
consultation 158
fallopian 382
Nervous 455
Moffitt 60
MR 344
LGG 301
Nine 82
MUT 301
WT1 311
Re 128
treatment-na 55
gastroesophageal 423
bolus 283
thymic 56
lead-in 496
IRR 421
dex 87
PP 222
AG-120 241
MTV 317
HBV 390
UM 308
nephrectomy 448
NMIBC 352
FIGO 382
IDS 383
RE 427
frameworks 46
attention 123
NRM 24
HMAs 264
CPX-351 63
CV 390
PNS 100
compounds 239
resources 13
irradiation 400
advances 245
Indiana 384
investigating 457
ly 95
chart 246
1.21 135
Ovarian 53
application 484
immuno 238
G1 271
urinary 459
salivary 357
occurs 302
Characteristics 305
Switzerland 169
programs 160
Cycles 432
treatment-emergent 26
blind 457
1.5% 489
230 218
1.15 135
responsive 80
stained 49
BCS 289
173 191
14.5 51
HER-2 163
DDRD 307
Pearson 439
propensity 430
overexpressed 321
Base 229
Hope 2
proportions 395
148 397
non-Hispanic 174
recommendation 46
false 209
routinely 292
operative 435
ine 176
Barcelona 253
carbo 187
pneumonia 26
FDA-approved 239
Recently 302
blocking 373
enhances 322
Sep 350
neu 178
mTNBC 80
stomatitis 26
12.2 412
chromosome 97
NED 297
192 122
traditional 155
15.4% 478
queried 229
items 210
0.012 313
continuing 304
13.7 412
preferred 371
0.048 313
venetoclax 469
maximal 324
transient 271
functioning 123
Birmingham 55
platinum-sensitive 414
platinum-resistant 414
ERCC1 402
241 429
substitutions 109
susceptibility 10
transfusion 77
CA125 341
BBB 31
Q3 220
EP 35
ATRX 241
STK11 279
food 285
VHL 483
recognized 245
commercial 160
clusters 235
marked 299
low-dose 87
testicular 390
protocols 193
10.4 412
neurocognitive 298
coefficient 200
PDGFRA 86
image 22
Olaparib 346
TPI 284
SMO 237
MB 343
SRS 400
proteasome 87
MEKi 190
WBC 236
BAL101553 467
vistusertib 346
immunosuppressive 322
fludarabine 67
Ipi 472
Atezo 340
CG 405
Cetuximab 144
right-sided 323
oligometastatic 400
FLOT 428
ECF 137
mediastinal 380
ABI 479
LOS 158
spleen 77
DAS 254
Lymphocytic 171
POM 87
Local-Regional 386
engineered 321
infused 67
synthetic 315
yielded 269
aspirin 465
investigators 90
insights 242
contemporary 74
modern 245
funding 46
EDT 463
News 463
Next 474
accounted 201
persistence 310
decreasing 165
nation 422
ions 176
ty 94
platelet 300
alopecia 26
Italian 224
Twenty 82
154 198
Brigham 253
BCT 449
centres 350
minority 245
315 451
P2 101
preventing 29
194 122
1.17 135
non-metastatic 54
Biomarkers 115
0.018 313
1.31 135
BCSM 168
0.6% 489
nature 298
rest 81
11.6 379
IRB-approved 244
fracture 252
LNs 1
scheduled 266
facilitate 242
datasets 235
1.28 135
sentinel 449
8.7 379
3.2% 173
signif 200
163 318
complication 459
Guangzhou 282
1.23 135
images 34
WBRT 400
trabectedin 427
FD 101
positively 297
signifi 403
reach 269
750 283
dendritic 322
cy 387
186 451
taxanes 357
null 325
9.0 379
barrier 31
agnosed 117
percentile 39
immunotherapies 327
FAS 427
exhibit 182
economic 46
interpretation 242
287 33
completing 16
Aug 350
biochemical 0
BICR 150
step 285
Interim 314
D2 283
generate 235
spread 136
pem 340
clone 49
ascites 473
killing 322
consisting 212
non-randomized 457
stereotactic 400
return 50
capacity 258
Prevalence 489
short-term 79
HI 220
suspected 380
understood 484
suboptimal 245
manner 216
disorder 459
268 397
uni 364
244 122
SNVs 491
sequences 311
ddPCR 170
gynecologic 219
measurement 481
TERT 273
hypothyroidism 438
depending 347
proved 420
encoding 321
viability 419
mutants 7
creatinine 300
cytarabine 63
Administration 4
IFNg 32
mel 184
Hh 372
Res 105
SRA737 496
IL2 32
clustering 235
azacitidine 63
castration 479
12.4 412
PVRIG 32
Q1 220
11.4 412
cet 402
ADJ 24
AFP 364
nab-PTX 401
closure 394
DF 99
ST 371
switched 446
296 218
cabozantinib 448
endometrioid 424
hypopharynx 20
ACC 284
admissions 159
gilteritinib 63
CML-CP 254
LGLL 64
ipi10 471
Childhood 263
CIPN 123
Karnofsky 250
Saturday 463
Portland 60
Arbor 107
preventive 102
v3 192
E2 458
issues 461
decades 245
volumes 34
Some 484
share 213
Onsite 463
entry 92
lymphoblastic 63
murine 322
pruritus 271
reduces 65
modulation 419
DS 289
DS-8201a 5
Instituto 353
1.29 135
evident 493
BCs 132
equivalent 50
relation 214
consensus 259
registries 114
NHS 466
epirubicin 428
confirms 287
Tumori 224
sessment 210
Sample 59
176 451
174 429
variations 97
FGF 370
CAP 163
propose 396
12.6 412
1.24 135
psychosocial 484
contribution 182
Antonio 314
questions 461
0.3% 489
9.1% 438
CHF 102
rec 193
incorporated 12
wide 182
199 451
captured 316
influenced 258
quantify 396
injected 347
light 339
typical 157
hy 275
procedures 395
66.7% 478
warrants 33
Not 270
273 122
Carboplatin 283
bleeding 459
Accrual 394
effectively 31
reg 176
ultrasound 34
derive 345
1.30 135
composite 65
Liver 404
hibitor 469
ondary 206
CALGB 447
Martin 169
Concurrent 335
PROs 295
reveals 182
challenging 245
source 158
insured 17
representing 105
lethal 0
eribulin 422
representative 162
tional 415
intent-to-treat 206
sistance 207
hr 300
incorporating 242
PRO 210
Inventory 295
stronger 32
explain 111
engagement 238
VEGFR2 458
0.0003 215
191 45
TTF 426
ELISA 473
Napabucasin 28
480 131
interferon 322
stratify 141
unadjusted 201
Academy 282
termine 155
GE 47
HBOC 10
whites 194
chemoprevention 197
centre 219
indels 109
IU 100
Southern 447
LP 134
classes 109
197 451
221 191
reads 109
intolerable 131
enhancing 151
metrics 317
disruption 203
real-time 391
vector 321
impaired 336
surviving 461
RAF 241
Hong 384
infusions 67
DTC 284
respiratory 272
ASH 19
fluoropyrimidine 447
FR 19
LAG3 73
CTL 32
intraperitoneal 382
liposarcoma 110
daratumumab 87
fol 428
Obs 137
OP 20
nutritional 484
PAC 175
FOLFIRINOX 440
Survivors 102
axitinib 448
344 5
BEP 35
SABR 400
CBS 37
RCHOP 281
Myelodysplastic 171
Syndromes 171
Allotransplant 171
BOS 413
MOR208 153
carfilzomib 87
Guangdong 282
NSCLCs 343
CRZ 58
PD1i 103
oncologic 160
Conversely 299
pop 407
efforts 160
simple 195
growing 245
cured 238
employment 461
pos 348
promote 275
Across 166
Gr3 26
Toxicities 26
synergy 373
1.26 135
Munich 447
358 171
processing 34
loading 276
840 432
guideline 74
510 204
concurrently 216
0.7% 489
227 451
TL 393
identical 44
NEJM 105
note 223
specimen 380
316 198
122 127
272 45
AKT1 7
weighted 200
behaviors 123
CI95 406
330 198
1.45 135
0.042 313
Combined 207
predominant 199
yo 98
Chi-square 439
vary 287
recom 89
133 318
294 191
scenarios 13
expectancy 92
comparative 181
16.7 51
sets 235
absent 211
SLNB 449
perform 44
Female 492
Value 270
beneficial 377
185 218
220 198
Novel 239
306 191
181 286
183 451
Chen 470
wall 251
called 474
Louis 107
Receptor 370
descriptive 265
Un 94
static 141
tation 7
primaries 492
quartile 313
quantification 83
interruption 272
Co 476
Tokyo 282
hemorrhage 459
ITH 396
22.2 51
16.3 379
AZ 226
0.021 313
Melbourne 60
paradigm 242
genotyping 96
CHT 356
Diego 2
PTs 13
Paclitaxel 428
D8 401
stabilization 366
upregulated 345
Sept 350
Family 53
1997 117
Associations 439
CTLA4 32
experiences 461
question 242
regressions 439
monitor 83
germ 227
proteomic 374
Uni 375
East 174
M1 293
P1 475
Recruitment 394
Exclusion 92
intravenously 432
RAD51C 483
HSP90 467
Level 276
NBN 483
adolescent 183
alcohol 194
clinics 160
missed 134
BAP1 483
tobacco 194
rolled 350
expert 193
missense 491
JAK2 273
examination 161
radio 400
removed 1
211 122
0.24 215
diameter 34
Tampa 60
RANO 329
14.9 412
regulator 275
14.8 412
EGFR-TKI 278
TRC105 112
hearing 123
OT 266
SUV 317
ii 418
multikinase 448
TRK 284
CL 179
TPM 342
noma 360
ifosfamide 18
Elevated 452
anal 335
CVA21 472
TIM3 73
dL 300
13.0 379
CMB305 238
HPV16 311
comorbid 194
DOC 479
CgA 355
ACRT 54
aRCC 448
p-values 439
MDSC 293
mobile 266
Ra-223 479
niraparib 164
Vigil 363
larynx 20
OA 394
ICU 158
TSS 77
hypomethylating 264
LSC 316
epithelioid 110
CTRS 371
Michigan 107
adenoma 237
alter 369
roles 369
ab 399
1.2% 489
IIa 234
promotes 322
combi 422
Cardiac 390
2.1% 173
anthracyclines 130
ypN0 209
149 127
179 482
Atlas 415
drive 327
CDH1 483
212 122
Follow-up 394
TH 266
numerically 426
optional 22
SEQ 401
Monitoring 339
q2w 432
damaging 315
amenable 477
304 318
aberrant 369
FGFR1 273
249 122
complementary 242
19.6 412
Therapeutic 107
categorical 439
marital 194
334 186
Histology 348
grading 210
1.22 135
exploring 33
W. 2
William 107
Docetaxel 428
excess 390
decade 155
235 122
159 204
LRR 431
161 318
Negative 270
rural 197
probabilities 12
Presence 385
bination 326
cantly 403
retro 363
223 451
ease 380
responder 255
plays 369
crucial 154
1.75 135
conduct 50
irreversible 469
Confirmed 333
CNAs 109
lumab 340
Serum 458
check 373
taselisib 130
characteristic 235
diversity 111
RIB 446
nd-line 447
eve 448
summary 44
subscale 295
214 451
288 218
Funding 140
hoc 115
Frequency 343
worldwide 160
La 2
relationships 213
Cooperative 250
injections 347
FBC 23
pared 468
Met 252
Andrew 107
insomnia 61
Herein 149
ge 361
t-test 142
Li 282
Paul 470
164 451
product 473
Evaluable 188
tar 5
225 318
Joseph 107
multicentre 457
HRR 489
units 43
PBMCs 473
260 218
explained 44
TD 77
Screening 156
15.2 412
sexual 61
participate 156
1990 162
service 158
245 429
mode 22
LatAm 201
237 122
Previous 416
Metformin 495
headache 271
Physical 295
12.3 51
Ca 386
EHR 265
ASA 465
pre-existing 74
AG 291
Ctrough 271
polymorphism 273
OCT 355
intra 299
dehydrogenase 241
determining 90
259 122
insertions 109
Cohorts 432
atypical 157
295 474
compares 358
duction 236
Anxiety 295
xenografts 419
functions 484
mouth 20
half-life 326
guided 317
exceeded 131
exposures 467
37.5% 48
ARQ 346
ADCC 322
Consistent 32
exception 124
selumetinib 496
C797S 278
Wnt 275
PBRM1 273
mono 144
vincristine 18
PDGFRa 86
E6 387
anti-CTLA-4 373
COMBO 421
BOR 210
SIRT 435
splenic 323
0.033 152
CTNNB1 7
ISS 348
cytoreductive 383
Paulo 169
5.6% 173
NPV 209
Y90 85
CA19-9 443
LAPC 423
vandetanib 284
BRPC 222
Depression 295
donor 24
indolent 281
cediranib 183
NHB 164
TTFields 31
admission 158
GCB 62
FLT3-ITD 236
NPM1 236
CRp 236
SGI5 19
Ibrutinib 19
NDMM 331
MLL2 7
mNSCLC 4
ipi3 471
IREs 342
ALM 241
LSS 84
DSRCT 437
Imatinib 86
Monday 463
colonic 323
limitations 245
driving 396
rise 481
adapted 90
Translational 83
unnecessary 195
elimination 341
Indianapolis 384
locations 381
intense 102
Campus 290
death-1 373
aminotransferase 271
CPI 80
ther 80
window 326
chosen 324
ity 176
cor 307
HRs 11
anticipated 394
multicentric 169
348 218
MP 18
surgically 6
machine 235
1.78 135
predefined 394
lumpectomy 449
surgeon 209
Healthcare 162
similarity 444
271 186
406 191
conversion 303
269 186
Endpoints 206
Fondazione 224
reason 16
Luminal 132
1.6% 489
Cases 305
T4 20
136 45
261 185
290 171
127 318
methodology 9
CE 216
17.2 51
Intermediate 40
West 107
ation 336
estimation 90
15.4 51
1.1% 173
magnitude 258
TNM 1
hybridization 163
receptor-positive 130
19.9 412
Duarte 2
Studies 302
non-significant 215
202 45
13.2 51
307 45
comprising 368
uninsured 17
consistently 269
deviation 210
157 122
Stratification 16
Lower 152
IIIC 42
dehydration 271
flat 324
Mann-Whitney 439
305 52
279 204
aOR 135
291 451
logical 385
char 305
fresh 22
184 451
Logistic 439
exploration 33
regular 265
powered 325
Hospitals 107
inhibited 419
normalized 268
proceed 325
vital 484
Richard 470
19.3 51
lab 109
Performance 295
Clinically 14
DoR 101
asthenia 26
U10CA180882 140
2.6% 489
intrinsic 214
1998 162
About 490
ulation 407
Status 270
16.6 412
13.5 379
interruptions 269
0.00 389
Exe 179
Asians 174
07 350
depletion 322
See 98
prescription 274
11.8 51
Denmark 169
launched 181
nomic 361
phenotypes 361
1.52 135
ns 313
PTX 28
detecting 228
definition 303
chromosomal 97
testosterone 488
enumeration 362
DL1 276
leptomeningeal 31
Ohio 470
BRIP1 483
Germline 21
Longitudinal 320
Information 162
determinants 470
partners 273
benign 97
SMAD4 273
242 451
Such 299
Milan 224
translocation 237
13.3% 173
condition 123
Large 2
Vanderbilt 60
kappa 485
1.10 135
0.024 152
1.38 135
life-threatening 102
valuable 292
limitation 245
distal 323
epitope 321
275 224
meningiomas 31
NF2 273
steroid 272
Ex 441
methylated 437
NNT 389
Evidence 5
respective 426
Rituximab 18
algorithms 265
pressure 452
TB 251
HV 337
produce 322
irRC 329
cCR 255
Myeloma 331
affinity 321
properties 419
Institutes 27
delays 41
Limited 377
NHW 174
Food 4
non-synonymous 415
Imaging 477
B7 38
sPDL1 364
Q4W 432
EU 9
mononuclear 473
doubling 347
625 276
SNF 273
advance 461
axi-cel 368
R2 297
JTX-2011 5
non-invasive 374
IFNGS 261
Wnt5a 132
Avelumab 340
0.019 313
intolerant 254
pelvis 100
rectum 323
EQ-5D 138
third-line 447
HRQOL 138
AP 428
HFSR 291
LT 1
1995 162
b-catenin 275
PCI 137
TUBB3 81
ART 390
PRCC 343
pT3a 431
CSS 431
ZA 300
TR0 170
PFS2 101
IMGN853 346
buparlisib 496
CNI 228
pCODR 46
parents 201
CPR 193
RUNX1 236
blin 26
AHCT 63
CTD 411
CPC 236
asbestos 120
coping 61
FoCR 461
IRN 67
therapeutics 242
carcinogenesis 237
cidence 102
products 213
Eric 470
behavioral 123
learning 195
built 235
AM-9 146
Precision 242
undertaken 298
17.4 412
anti-CD19 368
EM 310
scoring 37
ted 176
immunogenic 238
ta 94
ten 91
Trastuzumab 130
end-point 206
uPA 399
Conclusion 446
ypT0 206
13.6% 48
Identification 242
Ontario 375
signalling 275
II-III 363
Hormone 130
attitudes 160
Trust 466
la 224
PPS 206
1.51 135
veliparib 346
discretion 90
Committee 90
discordant 182
351 218
3.3% 173
sections 96
Range 51
preservation 29
1.34 135
1.44 135
1.39 135
1.47 135
12.8 277
activate 322
slides 49
267 291
progesterone 132
unfavorable 141
Independent 188
mid 181
enable 242
MO 2
210 122
Older 488
abstracted 162
14.4 412
289 171
facilities 17
BMD 488
gains 97
Essen 384
innovative 242
immunohistochemical 49
377 191
178 127
Sensitivity 209
tailored 195
helpful 195
Physicians 156
NM 111
TCS 159
red 176
002 61
CPS 73
According 9
0.039 313
insight 242
Target 394
16.4 277
emergent 26
CB 70
immature 358
Thrombocytopenia 26
intended 242
iden 97
meta 363
14.3 51
U10CA180821 140
muta 237
255 122
escape 369
RNAseq 96
6.9% 173
Population 27
accounting 439
syngeneic 32
MHC 5
3.0% 173
3.7% 173
chemotherapies 164
222 455
16.8 51
16.5 412
estimable 379
gallbladder 199
7.5% 173
composed 166
264 218
324 218
196 451
4.9% 438
PT 265
genotype 225
Adj 270
AZD4547 130
Spearman 200
Canadian 453
weak 49
discovered 361
DLs 324
Dose-limiting 276
1.64 135
solution 41
LLC 27
transcripts 316
versity 375
mature 358
sporadic 491
CIN 134
killer 322
exclusive 7
ancestry 10
OVC 178
Liu 470
0.028 313
DL2 276
Inhibition 275
illness 484
HER3 207
Test 295
accounts 376
apatinib 58
terminal 158
MUTYH 483
0.026 152
265 345
Internal 282
Hispanics 201
POLE 483
perceived 461
NJ 230
interactive 195
language 193
Relative 393
loci 361
FM 491
elucidate 33
visual 123
cooperative 453
respondents 201
glucose 300
Ki-67 49
stomach 424
1970 490
rising 274
medulloblastoma 263
ao 169
266 122
Utah 53
aid 195
PPV 328
checkpoints 373
meningioma 97
254 122
dismal 296
antineoplastic 5
patient-derived 419
6.7% 173
NTRK1 273
fluid 380
17.5 379
pansion 234
0.00001 313
SWI 273
caused 336
subjected 96
efficacious 287
crossed 394
LA 434
sizes 181
Post 347
HLA-A 189
V600 184
worst 288
PDGFR 469
TEAE 26
infusional 283
Solid 150
mandatory 22
anatomic 381
charac 305
S1 334
HLA-DR 293
340 218
700 429
IDO 322
transduced 338
anti-PD 340
OX40 32
suppressive 32
networks 369
MCC 472
HRadj 389
permitted 131
005 138
interquartile 39
effusion 459
CCA 284
I1 333
Winship 253
muts 491
HIAA 355
Lymph 1
442 122
BSI 43
PH 84
Costs 274
Olap 425
BCP 405
SR 12
PAMi 433
negativity 411
hospitalized 158
SH 84
discharged 17
reimbursement 46
NICE 46
end-of-life 158
GDP 181
admitted 159
BCL6 62
SCNSL 319
INCB050465 153
G100 334
Dyscrasia 171
Len 87
HDT 69
MGUS 331
HDAC11 419
SMI 43
onycholysis 41
CCSS 263
inducing 322
challenges 74
Because 465
fatty 203
investigations 396
people 490
scientific 213
closely 361
highlight 155
Fi 476
Mark 107
21.7 412
33.3 51
terations 491
clinician 195
CTL019 310
CTL119 310
BMS-986156 334
mary 14
Conc 176
Cannon 60
focusing 155
Ad 67
closed 394
hormone-receptor 168
non-inferior 401
1.57 135
206 429
annually 161
markedly 495
0.0% 173
Free 270
operable 6
281 218
NRG 384
Nazionale 224
lo 224
sequentially 432
1.53 135
5.8% 173
EPC 405
premenopausal 130
282 286
Affymetrix 96
CDK6 372
disparity 74
Radiotherapy 335
283 122
1.63 135
yoga 61
details 196
mood 61
21.4 277
Northwestern 107
coupled 374
dedicated 193
ference 196
0.8% 489
3.1% 489
6.8% 438
2.7% 173
Longer 358
acquisition 182
agnosis 117
Significantly 152
0.049 132
numerical 288
1.36 135
550 455
pathologically 54
Findings 197
all-cause 220
conducting 29
performing 209
basal 297
299 442
19.4 412
560 19
Model 265
techniques 161
efficiency 29
technique 22
343 218
Mexico 392
indicator 155
Vall 253
362 286
Thirteen 82
continuation 446
downstaging 137
EG 137
arrest 275
discontinue 178
carry 483
Hence 420
378 171
Pfizer 140
emtansine 130
censored 101
325 198
Anemia 26
224 198
IPAT 371
Akt 372
extracranial 329
9.3% 173
HRAS 372
D15 225
shift 274
remodeling 275
contributed 74
ministered 324
wi 176
amended 324
app 266
arthralgia 271
restaging 344
Week 138
20.0 277
modification 269
TAM 66
16.1 277
15.3 51
20.6 277
ments 246
292 221
match 109
nsSNPs 279
silico 235
1.96 135
brolizumab 340
hypotension 271
hybrid 109
cores 49
unstable 361
ADP-ribose 315
pre-clinical 207
Once 324
CHC 123
Nevertheless 245
960 131
2.4% 489
Understanding 74
Kimmel 470
actual 195
LPV 491
participated 156
rel 153
discussion 13
Change 303
viral 56
Renal 448
Fred 72
Hutchinson 72
formal 487
Mount 107
dominant 34
mitochondrial 203
conditional 217
219 218
12.1 412
transition 376
microbiota 111
301 455
WM 153
cation 196
constructed 439
expand 238
provision 193
recognition 238
proximal 34
dose-finding 284
257 122
profiled 109
Osimertinib 278
formulation 346
TGFb 112
ph 144
Dallas 494
20.4 412
resections 22
B2 276
Combining 336
0.022 152
strength 258
tastasis 307
influencing 196
321 191
phases 324
equal 187
caregiver 461
Induction 434
ERK 275
attractive 239
mitigate 484
od 324
venous 459
Cincinnati 263
requirements 195
SP142 49
CD 298
tipiracil 496
VEGF-A 112
NOTCH1 7
transformed 153
Wisconsin 474
WI 153
Selinexor 283
ATB 313
ICB 111
interstitial 459
IFNG 73
NG 311
chemotherapy-na 479
cost-effective 12
panitumumab 447
FOLFOXIRI 447
BG 300
0.010 288
IS 116
CCR5 402
post-surgery 395
1999 162
post-chemotherapy 138
discharge 17
BINI 184
ENCO 184
overlapping 311
intolerance 16
RI 281
adv 340
EAC 22
rescue 18
317 191
Pazopanib 183
CMT 162
ERT 335
PPD 307
RN 400
DRD 433
Trop-2 479
mpMRI 317
PCD 40
AGO 169
nerve 385
PCS 159
ICT 238
wastage 46
decitabine 264
CP-CML 254
SLL 153
B-R 411
CHOP-R 411
obinutuzumab 19
WD 330
DMB 300
MOR202 87
ELd 411
Ld 411
GNA 495
TET 56
CBT 266
GISTs 86
Del-1 339
THU-Dec 32
emergence 31
Potential 39
extend 287
discussed 195
Subsequent 67
dietary 258
minimize 484
20.3 51
Objectives 349
dose-dependent 326
tho 94
ls 176
node-positive 130
Optimal 384
pN 168
397 286
Estimated 291
biosimilar 140
278 218
CIs 11
248 186
Specific 270
410 455
1.95 135
converted 22
tamoxifen 130
dei 224
enrolment 394
liposomal 309
0.043 152
Distant 307
395 185
drop 247
fre 182
15.8 51
involves 376
392 191
fertility 395
263 45
1.8% 173
magnetic 228
303 185
tended 215
confirming 29
470 286
SEER-Medicare 162
4.5% 173
4.8% 173
1.87 135
0.0 332
393 455
Kelly 470
1.66 135
favoring 325
414 204
strongest 141
lymphatic 209
cut 430
attempted 391
device 59
216 122
Descriptive 439
204 451
Hebron 253
mechanistic 396
331 191
immunological 472
1.7% 173
Inclusion 424
50.0% 173
favorably 358
varies 155
British 162
consented 350
kit 96
abundance 142
0.045 152
lifestyle 258
Platinum 464
excision 6
immu 472
IHC3 163
METABRIC 132
radiology 150
Planned 150
23.5 412
jective 206
proteinuria 271
ID 453
28.6% 438
16.7% 173
226 122
co-occurring 237
0.027 313
tastases 435
dem 36
6.1% 173
compartment 34
cox 217
412 191
simultaneously 321
18.2 277
mon 176
reasonable 88
Q 276
Matthew 107
13.4 412
Andrea 169
Fifteen 82
overlap 97
First-line 95
resolution 344
well-being 61
varying 285
14.7 51
demon 340
ENT 132
IC50 419
Jewish 201
guidance 193
industry 46
adhesion 369
Project 27
RTK 273
pnsSNPs 273
rational 242
mesenchymal 376
Liquid 374
custom 96
accepted 155
link 213
differentially 316
mors 361
feature 235
ECHO-202 314
Alexander 60
consideration 292
achieves 325
ultimately 245
inadequate 480
lected 83
EudraCT 457
poly 315
Randomization 164
splice 361
intracellular 275
Columbus 470
Kd 419
PMS2 483
LCS 490
diet 258
genetics 10
policy 274
hotspot 109
Norris 447
breakthrough 41
Lake 53
environment 267
searched 221
349 218
0.023 152
Sinai 107
262 122
TCA 213
373 171
centralized 363
sociodemographic 162
233 186
234 45
TMP 10
11.1% 48
Yang 107
14.3% 173
243 122
Nineteen 82
metabolism 275
cerebral 294
Afatinib 278
I-8H9 436
irradiated 400
special 102
angiogenic 112
gross 59
diffusion 34
thera 327
VF 195
vival 206
thresholds 200
HDMTX 18
Basel 169
elevations 272
disrupting 5
pre-operative 161
ROI 34
wildtype 315
IWG 188
309 455
BP 272
beam 400
amylase 271
unmatched 163
hibitors 315
GMI 427
pregnancy 395
carcinoid 199
country 46
PB 473
A2 276
membrane 275
Aurora 60
FTD 284
372 186
cross-over 427
NCT01693562 47
CUP 56
gland 357
steps 210
Glasgow 466
Ref 332
replication 275
387 171
EXP 284
Nanjing 282
arginine 419
corticosteroids 272
RA 66
hierarchical 235
370 455
hemoglobin 300
abundant 299
CRs 333
PDL-1 142
Atezolizumab 340
acral 56
TRE 432
Pre-treatment 473
genitourinary 390
23.6 51
Curie 290
252 186
mucinous 199
defining 237
Per 397
LPT 402
1.32 135
Cluster 493
357 218
encorafenib 184
ECX 137
sb-PTX 401
DKK1 345
amcasertib 28
Kong 384
brachytherapy 400
380 171
CGA 180
tepotinib 284
mPDAC 440
intravesical 352
TGCT 124
Nx 448
validity 46
re-challenge 103
FACT-P 295
CaP 0
ONA 479
GYN 372
CMR 426
HGS 414
EMT 361
TTI 229
ESAS 295
HGBL 62
CPM 395
extremity 449
WTP 12
IPSS 64
DNMT3A 236
depressive 61
Lenalidomide 87
R-CVP 281
OPTIMAL 19
TGR-1202 19
COG 63
len 87
VRD 411
Pom 87
DURVA 87
Amp 84
impairments 123
cg 123
CIOF 392
TAL 324
INI1 330
Pennsylvania 470
reliable 209
remarkable 269
Targeting 373
astatic 244
concept 396
survivals 232
lifetime 258
lapatinib 428
skills 266
Duration 270
listed 248
benefited 278
sion 341
exhibits 207
biologically 334
vedotin 309
0.035 152
ferences 196
Short 295
Universit 169
five-year 137
amendment 324
omission 449
insufficiency 272
Consortium 27
Van 169
Pathology 392
10.5% 173
1.46 135
1.69 135
NST 395
323 455
ILRR 168
ER-positive 130
1.55 135
401 286
grant 453
anthracycline-based 428
5.1% 173
3.4% 438
q3 276
Addition 428
335 218
putative 483
hair 341
staff 193
Aim 356
item 210
comfort 461
217 122
Brief 295
14.1 412
14.6 412
23.1 412
19.5 277
NanoString 316
portional 217
resonance 228
333 429
distinguish 418
1.48 135
1.3% 489
aCT 141
lobular 199
1.72 135
7.7% 438
Georgia 229
258 122
NYU 230
entered 9
Calgary 375
AB 375
18.1 51
14.2 51
398 146
specialized 158
build 235
correct 265
PMT 194
1.62 135
Miami 2
lecular 237
3.5% 438
lymphadenectomy 335
Systemic 120
responsiveness 327
37.5 51
managing 65
1996 162
educational 461
What 21
opinion 13
mapping 238
Factor 370
312 186
367 146
impacted 194
refused 82
25.8 51
strata 141
11.5% 48
apy 164
Ali 496
enhancement 34
cyclin 372
talazoparib 346
Jennifer 470
George 107
paucity 302
partially 65
363 146
proceeded 387
ized 476
pronounced 215
radiosurgery 400
4.2% 173
EOT 225
Mar 350
tumorigenesis 237
Pretreatment 473
IFN-g 32
345 218
2.3% 489
ug 276
Intratumoral 322
material 22
22.4 51
alanine 271
C.I. 412
joint 124
valid 209
prolong 287
minus 379
Diarrhea 26
FACT-B 138
front-line 164
339 286
8.2% 173
Benefit 375
modifications 254
Bu 337
17.4% 173
till 16
cross-sectional 298
2400 283
Eastern 250
Men 479
18.4 51
lytic 294
Diagnosis 71
Act 274
V. 184
impair 123
pri 14
Trop2 362
transformation 153
PI3KCA 273
08 189
251 218
alleles 189
ported 271
Foxp3 293
Tennessee 60
RTKs 273
GR 431
reflecting 288
0.032 152
IGF1R 362
gressive 302
genome-wide 97
Race 174
Whether 155
infiltrates 293
boost 335
SV 279
286 185
M2 293
declines 479
KEYNOTE-037 314
Peking 282
EpCAM 362
Q4 220
restore 315
mediate 322
innate 322
Serial 83
smoldering 331
amino 203
GCR 76
447 191
forms 10
obtaining 154
irst 94
blacks 201
designs 29
tertiary 219
17.2% 489
Sidney 470
374 171
5.2% 173
devel 327
opment 327
paraffin-embedded 96
minorities 74
non-BRCA1 483
phone 266
analyzing 97
Salt 53
UT 53
NTRK3 273
003 189
Survey 295
0.046 313
oncological 298
Panel 455
internal 109
testis 199
Sex 194
prominent 369
contributing 195
419 218
generalized 439
Detailed 298
386 171
case-control 263
favored 137
single-institution 246
rhabdomyosarcoma 110
229 122
Nearly 274
mea 295
Patterns 390
3.6% 438
introduction 254
MGTP 13
COs 13
patient-centered 195
trained 193
beta 465
morphological 34
rGBM 437
Recurrent 21
astrocytoma 378
AZD3759 31
neurological 14
476 429
341 218
Hopital 290
Laboratory 282
radiomics 317
pseudoprogression 344
qPCR 473
lysis 310
USD 286
classic 301
Receipt 84
20.0% 478
spatial 142
enabling 238
retained 299
ALCAM 369
reflected 341
VB-111 437
hypokalemia 271
CD74 215
block 369
CSI 220
CCC 382
Technology 282
314 198
318 198
Acute 459
solitary 381
Jeffrey 60
IgG4 38
gap 274
bilirubin 272
investigator-initiated 453
Merkel 56
900 276
IMPACT 279
FFS 162
tivity 349
Cumulative 450
GMI-1271 63
adeno 199
Tumour 466
S2 334
Anthony 470
confirmatory 33
trifluridine 496
Lu 477
Progressive 366
1108 47
covariate 430
phosphorylation 275
trans 66
Tas 324
Palb 324
multi-centre 457
attained 296
exceptional 413
eval 340
mitotic 86
tesirine 309
NEC 181
III-IV 424
Q2 220
genetically 321
manage 254
mela 360
lymphodepletion 67
papillomavirus 434
malig 373
transfer 238
antibiotics 266
20.8 51
sign 298
IL-10 472
Maintenance 164
droplet 83
cachexia 15
bulk 316
09 189
VAN 112
hyponatremia 26
42.9% 478
Dermatology 290
locoregionally 423
inflamed 293
1302 234
CD47 38
N2 54
ablation 444
anti-VEGF 144
CRCs 402
CMS1 493
0.020 152
482 218
Abramson 470
SCRT 335
robotic 435
ceiving 84
22.1 51
Comorbidity 194
Quantitative 317
binimetinib 184
PVT 138
esophagogastric 423
biliary 423
RAD001 428
curable 298
nutrition 266
abdomen 220
Norway 162
indel 491
instruments 210
NENs 423
knockdown 419
0.0004 152
NAs 479
NHA 479
AR-FL 458
PCSM 431
Deg 352
LNE 449
NOVA 164
Plat 164
gBRCAmut 425
PAN 308
neo-adj 6
KELIM 291
Moores 2
LMR 430
PORT 54
TPF 335
MAN 194
Watson 193
NCORP 156
Inpatient 158
bank 193
CCyR 236
CMML 64
MUD 24
UTX 19
PI3Kd 153
elo 87
HRC 39
NAA 221
BTZ 495
ES-SCLC 35
MWA 291
HER1 132
MUM 308
V600K 7
GKRS 354
HADS 295
Unassigned 33
cRIT 436
DD 330
LPS 330
Db 449
RIS 227
RASA1 7
accessible 462
obesity 258
socioeconomic 194
conclusion 291
collaboration 487
chi-square 439
Financial 461
mor 44
Antitumor 349
H-score 49
280 455
25.6 51
lus 95
dioxygenase 322
ficacy 422
GV 236
ll 176
IIB 405
intention-to-treat 9
drawn 209
HER 132
28.6 51
transcriptional 369
418 186
376 191
unchanged 201
unilateral 449
equivalence 444
8.5% 173
subtyping 374
Ongoing 33
1.85 135
347 218
0.029 152
menopausal 395
close 395
390 171
cooling 29
Diseases 470
CIA 19
1.42 135
SQ 347
0.038 313
17.7 51
Endocrine 306
319 204
non-MBC 23
11.3% 173
19.2% 405
Demographics 350
pathologists 9
Gynecology 384
297 191
Even 36
3.8% 438
006 17
5.5% 173
48.4% 201
RDI 98
CCR 423
correctly 235
durations 426
Very 197
1.37 135
22.5 51
confounding 439
LSG 209
4.6% 173
SAS 439
lym 62
Predictors 292
su 176
MEDI4736 432
Pathologic 297
18.5% 406
66.7 277
15.0 51
q21 276
negatively 369
Chemo 428
Service 290
cardiotoxicity 102
returned 44
variate 439
22.2% 48
usage 201
Steven 60
Cologne 384
view 156
Vancouver 384
inconsistent 9
Ireland 466
SL 402
paraffin 22
frozen 22
library 96
quantity 288
clarify 74
1.43 135
benchmark 13
BD 276
ensure 487
palbo 306
ideal 238
HER22 130
31.4 51
365 146
op 95
Visceral 270
21.4% 478
Madrid 253
eventually 245
degradation 275
color 331
subclonal 182
highlights 374
fractory 234
Palbociclib 306
arrays 96
subscales 138
companion 374
bi 83
tained 81
padj 403
limits 245
activates 322
DCs 238
Kg 432
Year 270
422 218
25.4 277
Phoenix 226
18.0 51
1.65 135
Spring 4
ranges 188
Few 74
endo 424
ien 176
UGT2B17 179
13.1 412
405 218
Jolla 2
Pharmacokinetic 467
Brussels 169
soluble 112
Thirty 482
embedded 22
Working 188
disease-specific 5
impacting 195
saliva 109
contact 251
market 46
TM 321
automated 22
split 141
1.93 135
Progression-free 426
But 249
0.0008 152
mutually 7
introns 109
rearranged 109
cycling 293
KAMS 293
GCIG 164
downstream 275
285 185
PIK3CA-mutant 36
calation 324
chemistry 320
once-daily 469
Anne 470
diation 400
Cabazitaxel 357
species 419
submission 394
irRECIST 329
ploratory 206
0.044 313
BARD1 483
cervix 199
4.3% 173
IPD 10
mammogram 197
332 198
Spanish 224
hybrid-capture 109
exons 109
CLIA 109
influences 258
DSS 307
proof 396
353 191
RAD51D 483
7.1% 173
fication 278
Affiliated 282
Weill 230
193 122
oc 421
col 83
melanosis 385
Chi 439
immunofluorescence 49
Racial 2
paid 13
208 455
mantle 153
mographic 162
5.9% 489
die 135
premature 102
USPSTF 197
dollars 12
12.0 412
transitions 158
chance 74
pat 176
366 146
Fudan 282
Lisa 107
423 146
evolving 242
OCS 160
sessions 266
oncolytic 314
platelets 300
mutation-positive 184
19.1 51
antiangiogenic 448
embolism 459
peutic 327
USL 17
prog 141
cytology 380
12.2% 438
9.6% 173
Emory 282
SNHL 123
addressed 484
IL-12 322
CBD 284
THC 284
Linear 265
hit 62
CCNU 39
D3 321
preceding 18
298 218
bearing 321
302 218
bronchial 199
persisted 152
308 297
morphologic 296
Immune-related 421
dementia 102
402 171
CAD 102
311 185
organs 381
dry 271
transaminase 26
BRAF-mutant 184
minute 300
couraging 334
ABBV-399 284
dependency 203
hyper 271
trough 341
phar 349
ERG 497
non-hematological 26
collaborative 487
effort 213
Review 46
extra 90
myocarditis 421
inability 265
teristics 305
HSP70 321
uveal 308
DE 324
inhibiting 275
421 218
Loss 315
CSC 495
Ia 234
causing 203
B7-H3 321
parental 32
cytologically 424
augment 322
translate 65
ated 28
Branch 27
MDSCs 473
sNTX 310
immunologic 368
Identifying 21
modeled 341
copies 225
403 186
Anti-PD1 373
CP1108 47
16.2 412
bulky 335
385 171
MGC 423
clonotypes 299
SMR 220
Ottawa 375
JAVELIN 340
Davis 2
ASPS 183
sipuleucel-T 304
MFI 295
notably 241
15.5 379
vaccinated 311
GBR 234
CAR-Ts 67
Hb 300
CSF1R 469
7.9% 173
FoundationOne 109
AIO 447
337 218
417 171
1.54 135
chemoRT 335
PET-CT 108
postop 225
Placebo 277
NRT 54
FP 447
Marrow 188
SAFL 402
Postoperative 383
retroperitoneal 449
EAP 409
Preoperative 335
Elizabeth 2
loco-regional 449
blood-based 83
21.9 277
firmed 82
APR 41
RSI 54
wait 383
Chest 282
PAG 291
CFP 405
minimally 14
CLDN18 81
RD 284
SRE 355
emergency 158
non-cancer 162
CON 401
TTPP 170
SLD 288
GS-5745 38
GVAX 352
IMDC 448
HDC 336
seminoma 128
HTA 4
measuring 484
HS-410 352
CTx 144
EPI-TAX 128
ECOG-ACRIN 470
MVD 141
407 280
mGSTP1 170
RNA-seq 316
PDE4D7 430
Weight 300
perspective 12
tablets 346
DP 137
PSR 346
non-gBRCAmut 425
decisional 393
leiomyosarcoma 110
CIV 283
MAP 18
RAI 284
mp53 307
ADL 295
out-of-pocket 274
psychiatric 159
PROQOL 461
GVHD 24
donors 265
alloHCT 24
IDH2 7
tAML 63
MPN 64
BGB324 419
COO 62
RTX 444
FL3 229
KCd 411
CASTOR 87
Sema4D 79
lobectomy 449
nonsquamous 424
EGFR-TKIs 278
EGF816 278
ex18m 278
LI 17
EXCAP 203
CARE 266
adolescents 183
antidepressant 158
mindfulness 266
NCP 102
SCP 13
EWS 183
FOXO1 365
ch14 32
LUQ 220
osarc 39
ELs 430
INFG 111
LTB 86
tortuosity 317
Bim 473
integrate 292
capable 238
enables 474
car 155
humans 5
synthesis 497
obese 392
linkage 162
Geriatric 295
billion 274
micro 415
technologies 160
seek 160
maintain 29
vision 271
IDEA 487
rst 476
NSG 419
CIM 40
platforms 278
GITR 32
aspartate 271
BMS 409
Sixty 82
post-baseline 210
rated 461
CPIs 257
durability 296
ce 94
animal 207
contralateral 395
87.5% 405
breaks 315
urgently 242
I-SPY 132
71.4% 478
507 204
ventricular 251
regard 196
508 218
adoption 160
accompanied 34
addressing 487
6.6% 173
withdrew 16
Summary 260
50.4 335
SB3 444
node-negative 449
1.0% 489
BCT-E 449
274 218
NSABP 384
Previously 391
0.034 313
anastrozole 130
factorial 19
AT 405
20.5% 438
assumed 325
012 447
Effects 33
bed 266
Virginia 107
binary 430
TAILORx 168
329 338
Assay 96
BFI 295
Sunnybrook 375
5.4% 173
15.6 277
assignment 394
381 171
mended 89
systemically 232
16.3% 173
Parts 234
add 50
Reported 14
2.9% 173
precise 37
I-II 54
Elderly 375
Langone 230
Its 155
Santa 53
subcutaneous 432
cause-specific 1
inferiority 401
vein 251
Demographic 305
24.1 412
prolonging 287
Androgen 497
Fifty 439
Nuclear 270
7.8% 489
9.8% 438
2.20 135
Triple 348
Less 201
evidence-based 193
Trabectedin 88
6.4% 173
236 122
microarrays 49
metastasis-free 307
importantly 307
580 429
HP 130
acteristics 305
myocardial 102
infarction 102
Yonsei 282
phenotypic 316
imen 176
Poly 315
Assuming 325
rma 176
Matched 109
Sanofi 140
Rachel 107
PALOMA-3 306
Questionnaire 295
worsened 14
1.49 135
11.4% 173
10.2% 438
13.2% 173
initiating 247
alpelisib 130
thor 476
administrative 162
Taselisib 207
suspicion 21
extracellular 275
Luis 290
prematurely 394
lationship 341
17.0 277
termined 341
toler 28
Laura 60
promoting 369
Com 274
lock 101
18.2% 438
metabolite 179
bound 44
IMP321 347
lentiviral 321
389 45
1.92 135
scales 210
inversely 203
retrieved 162
media 265
logy 94
399 171
TKD 273
easily 195
Gemcitabine 440
CellSearch 362
Weil 230
Relapse 307
calls 109
7.4% 489
slow 166
pital 290
macrophage 32
indoleamine 322
geting 373
guiding 292
Design 457
tucatinib 496
recruiting 396
heterozygosity 315
Terminology 192
co-primary 206
Archival 49
35.5% 48
Jessica 470
referrals 10
cessation 193
PCPs 461
CTs 193
modifiable 258
tudy 176
nationally 201
preventable 17
394 218
allelic 97
Rare 21
MRMC 197
PCA 10
univariable 194
Through 193
WB 473
429 218
Seventeen 82
histories 491
Second 447
agreed 461
WGS 109
V2 485
356 218
neoplastic 34
morphology 399
icant 79
differentiate 344
Wilms 183
aberration 237
322 185
dysplasia 6
endoscopic 22
prescribing 46
societal 12
1.79 135
Physician 158
16.0 277
specialists 193
insulin 258
vari 203
correction 439
Christine 27
funded 453
LFS 203
disposition 258
1.74 135
PNI 392
mm3 203
HRT 74
fail 245
4.7% 173
Gender 381
FMF 162
strated 340
insignificant 141
distance 194
Biopsy 344
SWM 174
ients 176
9.7% 438
tumor-specific 369
GB 204
Implementation 13
structure 258
investigates 368
Frederick 60
DNX-2401 472
Canter 60
ABT-414 437
titration 324
mCi 251
unmethylated 437
emission 108
Zurich 470
Multicenter 453
segment 234
processed 96
carci 423
p19q 320
Bologna 224
19.4% 478
404 218
Expansion 67
failing 80
anti-angiogenic 336
isocitrate 241
bp 109
Propensity 439
TNT 335
Programmed 373
LOT 87
359 218
dizziness 271
imbalance 97
And 383
dimensions 341
carrying 86
ma 94
Twelve 284
SHH 110
Their 128
sponders 297
silencing 419
SNV 109
313 191
hem 62
tol 496
structured 193
auto 24
crease 299
hypophosphatemia 271
MDM2 241
t1 179
hold 269
Ventana 49
18.8% 173
lactate 452
G1-2 271
Ph2 183
Case 226
092 346
AGC 401
BAL27862 467
recruit 394
reflects 155
flexible 195
systematically 160
Selumetinib 324
AX 284
bioavailable 469
Five-year 173
repeat 380
veloped 385
DPYD 149
Log 439
416 186
Minimal 268
Rapid 93
qRT-PCR 96
optimized 321
MTC 284
Checkpoint 373
Open 457
stimulates 322
bacteria 111
BCMA 321
nancies 153
Cells 321
KTE-C19 368
transaminitis 272
immuno-oncology 242
Groningen 470
IIIb 42
17.1 51
neoepitopes 299
CRISPR 369
carcinomatosis 382
CD11b 293
26.7% 438
26.5 412
mm2 293
intestinal 424
topical 484
Eleven 82
UBC 47
q3wk 276
LV305 321
pegylated 35
IMiDs 87
PIs 213
Daratumumab 87
EnAd 472
80405 447
19.0 51
11.7% 438
logrank 217
18.7 412
338 218
396 171
flexure 323
expensive 12
FBXW7 7
Con 333
MABp1 291
6.5% 459
TAS-102 231
17.3 412
18.3 412
HCQ 428
383 171
IRI 437
multi-organ 99
BRAFm 184
nadir 481
ICD-9 162
VS 351
densities 293
v2 317
Jonathan 470
24.2 51
multicohort 340
lip 20
lowed 428
CVA 102
EGC 360
FAST 81
TET2 236
dying 102
ECs 312
MMP9 275
capture-based 109
MVI 430
PMCA 328
analgesic 123
mtx 443
Charlson-Deyo 194
fs 491
Mannheim 384
lymphoid 321
MIBC 54
insertion 109
426 45
platinum-refractory 340
TAX 276
CaboNivo 333
FoxP3 293
Favorable 406
nx 142
receives 432
PSA50 14
flare 14
BEN 153
364 146
ACM 69
CD163 293
354 218
ICS 159
rating 46
full-dose 465
PDS 395
generic 274
CHO 32
CD34 236
pre-RT 84
MTB 193
prices 46
affordability 46
HAS 46
transparency 46
HEC 41
WFO 193
Guidelines 2
MPAL 64
EASE 266
TRM 24
allo-SCT 24
FCR 19
del17p 19
MZL 153
CD30min 387
Bv 18
CT-P10 444
POD24 452
KI 254
POLLUX 87
ISA 87
CVAEs 260
LoDEX 87
FLC 339
DCT 87
Pd 409
L-LCNEC 343
MDC 3
pleomorphic 110
LD 337
DCB 343
ABP 341
NSCLC-ct 416
TMT 138
IRE 118
aCTLA4 421
haloperidol 266
VRM 399
NPLC 121
LWC 158
SIPAT 123
filgrastim 19
NEPA 41
VITD 488
rVITD 488
AET 266
SJLIFE 263
SLFN11 321
MSF 381
SOT 390
UPS 110
LMS 110
RAO 39
LMTK3 419
ASTS 427
MAs 237
pTie2 341
AAT 207
exosomal 339
PND 21
CETCs 32
nanomechanical 399
Award 27
PACE 254
Brian 470
Jean 107
exceeding 18
Can 169
unable 50
Bren 384
survivor 258
oxaliplatin-based 428
metas 294
agement 195
Pancreatic 282
commercially 174
Oncomine 109
attribution 271
GDC-0919 334
Howard 60
Related 26
wider 154
topoisomerase 207
broader 238
inh 372
Gastroenterology 169
Long 354
504 204
29.4 277
2.70 135
docrine 199
Surgeons 282
7.6% 438
TRZ 444
45.8% 405
Sara 253
Interval 135
512 286
juvant 446
decided 394
parameter 341
Charles 107
432 218
460 286
523 191
chemotherapy-induced 29
CCND1 273
scalp 29
Variables 194
1.61 135
1.77 135
3.12 135
2.16 135
QLQ 138
Adding 422
21.1 51
Kansas 2
stepwise 217
568 279
Mx 449
3.9% 173
533 286
IHC2 163
medullary 199
immunohisto 49
T-stage 430
740 286
1.58 135
536 286
archived 399
44.4% 48
co-expression 293
cutpoints 430
highlighting 396
Tel 2
409 429
Lima 353
Peru 353
pT 430
1.40 135
pN1 1
priority 242
23.1% 405
rich 29
448 286
ciation 439
Oncologists 193
Role 280
reliably 195
pre-specified 206
icantly 200
Surgeon 197
Selective 275
PST 209
LVI 1
562 204
SLYMPHA 449
lymphedema 71
derwent 128
dence 260
diotherapy 335
Americans 174
336 122
Anna 384
9.2% 173
32.7% 173
2.95 220
rece 176
Concomitant 477
analog 467
taxane-based 130
Protocol 360
HER2-targeted 132
amount 265
strat 195
CbD 405
Y. 107
AUC5 283
possibility 29
selecting 155
Sites 380
stability 315
initiate 487
exp 176
ial 176
Enrolled 101
355 218
368 146
hypotheses 394
43.6% 438
viously 106
q28d 432
Sec 206
vinorelbine 35
refine 195
fitted 217
locus 97
de-novo 299
0.047 152
ro 176
MSAF 491
cance 94
MONALEESA-2 306
fa 102
408 186
23.7 277
58.8 277
spectrometry 268
informative 235
equivocal 163
elicit 238
Ltd 38
CT26 32
sug 267
38.5% 438
esti 217
Serious 26
427 186
recur 31
GPA 317
microscopic 399
distributed 201
18.5 51
15.0% 405
persists 74
structural 361
Mut 7
constitutive 275
Samsung 384
ful 306
Nausea 26
TOI 138
22.5% 438
32.0% 438
Though 152
inactive 321
Larger 33
15.9 412
20.8% 405
percentages 32
preferential 419
cology 282
chemoimmunotherapy 281
recombinant 38
suppress 275
histone 241
30.6 51
differing 196
sparing 465
BOM 232
2.17 135
subpopulation 232
4.03 192
expertise 193
Consensus 140
extract 265
253 122
confined 381
serves 242
Caris 109
chemotherapeutic 239
microtubule 38
Alabama 55
de-escalation 335
G-CSF 276
CR1 236
correlating 255
matrix 275
ECM 364
0.041 215
1839 28
1.88 135
Grades 26
Unlike 301
integration 111
277 185
CNA 109
character 305
genomically 361
1.50 135
FOXP3 293
on-target 326
epacadostat 314
Epacadostat 314
CD56 473
Available 83
Montefiore 230
Poland 290
conjugated 38
tolerate 18
suppl 464
deliver 89
oxygen 467
microbiome 111
CD138 331
signed 49
Benjamin 470
Exome 109
Ashkenazi 201
surveys 158
MGPT 10
verified 244
17.6 51
Cervical 335
Public 27
prepared 265
Importantly 369
BCSR 197
HRMC 197
1.9% 489
associate 361
Gray 11
elements 213
carrier 10
incidences 137
oncogene 273
formalin-fixed 96
coded 162
Non-Hispanic 174
15.8% 478
Integrated 27
I1307K 483
Pathogenic 491
nonsense 491
codon 7
sources 124
off-label 239
request 10
requested 391
Besides 182
examining 249
whole-exome 109
tified 97
Foudation 53
multifocal 380
preserved 293
metanephric 237
pathologist 49
adenomas 194
Soft 385
Squamous 386
391 186
415 186
publications 4
offering 242
square 439
disability 17
19.7 51
20.7 51
OHD 458
unaffected 53
1.83 135
Kit 96
marketing 193
Detection 228
background 44
lorectal 312
household 201
computing 193
rarity 302
596 218
0.0009 313
proliferative 322
1.70 135
transgender 395
etiology 484
hematopoiesis 182
fiber 258
1973 114
entity 155
Dako 49
uncertainty 195
Pos 201
Neg 201
display 315
Endometrioid 424
24.5 51
Clinicians 195
Fox 2
Chase 2
certified 156
gamma 5
live 265
lomustine 496
EGFRm 31
20.1 412
NCF 288
texture 317
druggable 237
sensitizing 278
cerebrospinal 380
call 195
calculation 206
Southwestern 470
Stephen 470
Mutational 343
60.0% 478
embryonal 183
profound 241
deficit 123
rRS 301
operated 54
284 185
surrogates 37
peritumoral 34
Poor 390
Rank 439
CD133 368
plasmid 321
cystic 199
Adults 310
Different 237
modalities 281
medium 200
Investigational 314
CTLs 293
1.90 135
artery 251
single-center 453
adversely 159
classical 321
cPR 333
CK 271
biomarker-driven 242
alkaline 271
phosphatase 271
LY3009120 496
dermatitis 26
hyperbilirubinemia 271
ABBV-221 234
436 191
bd 276
NQO1 73
assesses 349
nab-p 276
Deflexifol 283
ministration 324
5.3% 173
Shizuoka 282
approvals 4
Forty 450
8.4% 173
microscopy 22
interventional 90
considerable 245
sponsored 453
Upon 347
compensatory 491
RO6958688 334
CZ 284
A1 251
nP 276
sensitizes 207
trajectory 158
HNI 179
ATLANTIC 47
Jin 282
411 186
subunit 273
HA 206
demonstration 349
FGFRinh 372
esophagus 423
chromatin 273
ovary 199
trigger 369
round 110
olaratumab 183
Vascular 112
Child-Pugh 92
up-regulation 32
radiation-induced 102
Gem 440
Sorafenib 254
remissions 296
M7824 234
CB-1158 326
Providence 60
heme 272
truncating 7
PRKDC 111
assist 195
Relationship 185
CCR7 473
Th1 32
FDR 293
vation 43
SP263 49
1.73 135
reactivity 311
antigen-specific 32
mTc-IL2 22
discrimination 209
nonrandomized 457
engraftment 419
high-affinity 38
x109 338
384 218
alveolar 183
G3-4 421
PA2024 473
PM-IPI 141
45.5 51
HPV-positive 434
lowing 6
NY-ESO 321
VISTA 322
undifferentiated 199
361 146
hand-foot 26
Klinikum 447
FIRE-3 447
592 415
CMS4 493
Classification 198
canonical 361
17.7% 173
327 218
net 265
stratum 194
Line 333
resectability 435
Sichuan 282
Depth 1
FN 134
MCRC 447
GHS 138
21.5% 215
SOX 482
STI 252
ablative 400
CETUX 98
faster 65
25.0 51
CRCLM 435
Yu 384
SCNAs 361
1.99 313
ms 313
Reasons 16
Others 218
Cape 137
intrahepatic 199
VENTANA 49
ORRs 333
prolongation 14
Kang 282
I3 333
esophagectomy 335
aHR 135
CAs 193
1.97 135
EN 137
2.01 135
optimally 35
Arm1 405
62.5 51
WHITE 408
TAS-118 85
DPAM 328
MPS 364
TG01 440
Alb 364
dates 13
KM 217
alts 257
424 186
poor-risk 227
COMPARZ 499
Taussig 226
UD 195
DOD 297
CaboNivoIpi 333
splenomegaly 310
ences 194
USC 491
treatment-naive 409
prostate-specific 479
aBSI 364
preC3 170
palliation 250
640 300
ARV7 479
deficits 123
HDR-BT 431
ZFP36 0
discrepancy 395
T-group 488
CTRL 488
C-RT 137
346 218
paz 28
losses 97
deb 6
drowsiness 61
IBM 193
biphasic 424
blot 419
blocker 249
alternating 19
modulated 335
326 409
LAHNC 434
non-OPSCC 434
APM 5
CRT45 478
TCs 56
payment 274
ESMO-MCBS 46
themes 265
RoW 174
LIS 274
avoidable 158
SES 194
spouses 461
wealth 461
Fitbit 266
Allogeneic 63
antiemetic 41
Exercise 266
RBC 77
IRAEs 100
BCR-ABL1 413
MCyR 254
IDH-DS 272
FIA 236
MOD 99
post-HCT 61
VEN 65
SY-1425 419
cGVHD 77
MSD 24
JCAR017 310
RSCs 369
Mel 343
Lugano 329
nasal 452
DA-R-EPOCH 281
CNSL 281
GROC 426
THL 62
COT 281
RAD 411
small-cell 282
TETs 56
ADCAs 244
ADI-PEG20 35
osi 278
Emi 404
ASP8273 223
METa 96
SCLC-ct 416
HF10 340
9514 137
RIBO 496
mMCC 73
MONO 421
ITK 322
KRG 138
post-intervention 266
PULSES 195
AAS 466
YAC 123
FBT 138
BBT-CI 266
MAF 170
HRV 61
elsiglutide 26
AIA 97
hVITD 488
SCTx 247
VCR 67
anti-GD2 373
pexidartinib 329
ADHD 123
SPPC 158
SFT 183
KIT-mutant 419
BOL 401
SyS 110
CAMLs 208
STB 86
sPD-L1 473
GRP78 293
YWBC 214
broadly 238
Sunday 463
learned 193
forward 160
acids 203
Scientific 27
professional 461
Patrick 470
choose 74
Lyon 290
Profiling 374
4.4% 489
widespread 245
isease 176
inactivation 273
hypo 271
19.8 412
40.1 51
causality 271
Chiba 282
reassessment 324
Pa 94
ditional 334
fined 353
0.9% 173
FEC 428
1250 283
503 204
43.5% 405
doc 144
conflicting 244
originally 394
exam 161
adrenal 459
58.4 277
mapped 109
491 429
supervised 266
Monica 2
Detroit 107
tuzumab 130
549 186
contained 209
2.0% 489
basal-like 132
whichever 16
8.9% 438
sta 134
11.2% 173
q2 276
X2 138
578 425
revised 90
CNVs 7
alyses 341
aiming 29
Cohen 200
observe 43
Young 282
Do 146
3.00 135
Management 392
YCE 138
documentation 266
C30 138
reaching 77
10.0% 173
28.7 412
Younger 194
dichotomized 235
converting 209
IDFS 214
initiative 160
1989 162
Obstetrics 384
waiting 108
541 200
pure 297
2.39 135
pegfilgrastim 41
ommendations 193
verify 90
provement 65
de-identified 244
Clinicopathologic 56
Tom 107
Late 390
17.8 277
27.9 51
30.3 277
28.9 51
equation 430
discriminate 344
1.68 135
Disparities 146
explores 234
1.91 135
inappropriate 74
supplemental 162
14.4% 173
22.7% 173
rule 394
operation 449
35.7% 478
SN 449
Sur 282
Version 317
drives 369
operating 430
intraoperative 400
navigation 160
CTLG 209
subjective 161
10.8% 173
569 218
Trends 158
2.13 135
transaminases 272
38.7 51
nab 428
004 393
Specifically 495
VEGFA 402
Training 27
Residual 170
admin 276
Deyo 194
steady 269
EarlyR 214
Pertuzumab 428
medically 160
formalin 22
stitution 117
volumetric 329
in-vivo 207
atrial 272
IBC 399
Statistics 217
Schedule 324
Palbo 306
ineffective 130
responsible 369
lethality 315
over-expressed 321
379 186
Pre-clinical 207
Geffen 470
20.2 51
ina 94
classify 97
tree 430
entities 4
TALA 346
tropenia 26
1010 321
Rebecca 60
ative 473
Charlotte 107
quency 182
Frequent 438
Kinase 469
opportunities 242
blood-brain 31
Neuro-Oncology 150
38.3 51
death-ligand 373
ICIs 373
fective 29
trended 403
4.1% 173
isoform 321
pancreatitis 272
individually 5
dosage 326
raised 5
1.84 135
separated 121
2.2% 173
25.5 51
create 396
Assessments 329
mixture 275
implement 160
25.1 51
24.8 51
18.8 51
universal 245
TSC2 433
frameshift 491
Fulvestrant 306
28.8 412
23.0 51
anti-estrogen 130
G12D 7
21.5 51
Difference 277
stline 479
Graduate 282
health-related 298
HER2-ve 356
describes 356
20.7% 438
ESME 356
EV 130
genotypes 458
328 122
AIs 130
Adherence 197
Eli 140
Lilly 140
indirect 200
Extended 463
corre 473
whilst 220
Starting 276
par 213
Treat 477
46.2% 173
Characterization 111
Marie 470
Location 348
Correlations 439
High-dose 308
counted 265
focal 34
MMP 311
spherogenesis 239
PNAS 239
customized 242
TP 41
Q12W 150
temporal 182
platin 187
comprises 321
Genome-wide 109
cally 38
believed 245
lymphovascular 1
mune 299
holds 245
Pacific 174
Regression 341
27.5 51
Tz 130
ALP 14
BYL719 496
Before 16
standard-of-care 164
Bronx 230
first-in 234
BRCAness 315
abstr 464
penetration 294
energy 369
du 290
pre-dose 473
onalespib 467
Georgetown 470
Lombardi 470
FANCA 483
read 265
Testing 163
28.2 51
Knowledge 21
underserved 461
radiologists 193
scheduling 160
Mammography 162
COMPASS 201
interview 193
supplementation 476
ascertained 21
12.1% 173
31.8% 483
notable 97
Personal 201
interpreted 195
les 176
CpGs 437
Normal 462
Differential 316
identi 244
counselling 10
Hall 470
lacked 273
break 131
Generation 474
splicing 241
timely 160
15.2% 173
8.3% 438
Collectively 299
V1 485
JAK1 273
spindle 275
purposes 160
migration 369
statin 194
palatal 385
neoplasia 385
articles 274
Veterans 2
Does 146
OPLs 316
biobank 27
Rutgers 230
Body 250
approached 219
MDs 13
recall 393
MAM 201
Pooled 340
awareness 13
incident 490
9.4% 173
475 283
x10-5 332
1.86 135
Icahn 107
doubled 173
dependence 77
ANOVA 439
Korean 453
stressful 390
Proportion 174
0.0007 215
23.4 51
21.8 412
pay 46
DA 195
self-report 210
facilitates 238
assembled 235
teaching 219
additive 326
IL-6 473
2018 193
leukocyte 321
IgG 32
ocular 319
PFS6 206
mitosis 86
Lille 290
342 171
intact 241
Glioblastoma 470
perforation 459
Neurology 470
positron 108
front 287
tumor-associated 322
rCBV 34
VU 282
CLIA-certified 96
Encouraging 28
tablet 346
yielding 426
STR 54
detects 109
implies 154
deleted 273
QAS 426
ndline 164
LFT 272
encephalopathy 272
latency 121
ternational 487
infectious 359
disturbance 459
Comparisons 439
regarded 302
Chris 183
counterparts 152
293 171
UCLA 128
launch 46
Under 203
phosphorylated 275
biologics 4
CXCR4 207
epitopes 321
VXM01 347
relapsing 245
partly 238
Cognitive 295
foci 22
cc 220
HUS 288
localization 275
Pharmaceuticals 453
acizumab 164
PTS 231
Int 464
ratings 461
mographics 162
fibroblast 370
Pharmacokinetics 334
GGT 26
dysgeusia 271
expressions 361
KRAS-mutant 7
actions 484
Carcinoma 386
EFNA4 234
Jason 470
637 286
82.1% 405
E-sel 296
antibody-dependent 322
cell-mediated 322
MacCallum 375
immunosuppression 322
adenoid 199
intra-patient 324
adequately 213
package 265
Bruton 469
VEGFi 112
Silver 4
hematology 46
Russia 282
Majority 64
pharmacologic 369
suitability 22
fasting 341
NRCT 246
experi 148
27.3% 48
lipid 267
chemokine 32
erated 496
dropped 478
castrate 497
DDFPe 347
ilorasertib 481
trajectories 274
CD80 38
AZD 264
Levels 299
GSK2141795 496
BRAF-V600E 493
scheme 324
pathogenesis 369
charts 244
mRNAh 372
dasatinib 254
lation 271
intention 426
Sunitinib 448
hedgehog 314
Hedgehog 275
desmoplastic 110
Notch 275
Rovalpituzumab 309
Preclinically 207
EphA2 321
Copenhagen 169
applying 265
portal 251
CEBPA 236
nintedanib 164
urgent 466
G5 272
clear-cell 448
retinoic 275
ZUMA-1 368
cytopenias 272
purified 369
15.7 412
miRNA 235
adoptive 472
MCPyV 73
evasion 369
kill 419
Rockville 27
interrupted 421
indoximod 304
consecutively 117
26.2% 173
compromising 65
B2M 299
IE 293
seeking 160
palpable 347
LTX-315 334
Biopsies 16
vaccines 238
INVAC-1 234
VG 405
anti-NY-ESO-1 32
multinational 457
NKR-2 334
TTI-621 238
poly-ICLC 432
B1 276
ARRY-382 234
metachronous 381
eli 92
CMS2 493
29.5 412
36.8 277
CMAB009 283
Colon 402
11.8% 438
glycemic 258
preop 335
Histologic 56
LCR 288
EGFRi 288
assayed 96
Regorafenib 469
expect 393
32.1 412
Concordance 218
benefiting 217
DSLT 402
conferred 200
hypermethylation 483
Staging 188
DpR 116
pmab 116
Prognosis 290
Queen 466
iri 402
MSI-high 343
SCNA 361
transcript 235
unfit 141
staged 54
Km 412
Sequential 428
UFT 54
Zhang 282
Yat-Sen 282
2.04 135
budding 1
hypermutated 361
IADL 295
cDLMs 209
55.6% 405
NI 315
Sor 409
Choi 282
stomach-preserving 137
nominal 389
rN 209
std 40
Wk 355
Eighteen 456
2.67 135
FGFR2b 38
TF 283
ticenter 486
BKM120 423
HCV 333
GAs 273
nonresponders 355
NEN 390
Detectable 170
balance 65
430 171
defective 315
quality-adjusted 12
QALYs 200
MV 217
PDA 374
reversion 414
reading 491
vessel 317
CrCl 300
14.0 51
penile 56
SETD2 273
IC2 73
E545K 7
FUP 227
GCTs 227
Cabo 448
castrate-resistant 479
tier 324
skeletal 43
586 491
CTC-positive 168
ys 431
N-terminal 497
PHQ-9 61
q4w 432
post-RT 170
2.18 135
weights 265
intensification 69
olap 346
mation 480
macroscopic 6
352 146
CTRT 137
OC-S 414
BRCAwt 414
Incremental 12
NSGO 169
OvCa 6
Ced 425
GO 201
PLD 283
382 171
payer 46
Ola 346
PM01183 346
CVC 480
ETW 137
OAW 137
LA-SCCHN 335
ECS 1
Nimotuzumab 335
SG 406
CCD 159
RT50 478
NBTXR3 347
NLP 265
conflicts 461
coefficients 200
topics 461
Access 4
shortages 13
Social 295
KP 174
MTBs 160
trust 393
zone 153
FACT-G 210
graft 24
PRE 250
aprepitant 41
Latino 17
aRR 135
valuation 46
MMS 12
DRG 34
JAKi 77
MR4 291
FLT3mut 63
non-relapse 24
post-HSCT 99
allo 24
mCR 366
crenolanib 19
TP53-MUT 236
higher-risk 264
myeloid-B 316
engaging 38
HCT2 24
RIC 24
MGD006 67
ofa 19
non-GCB 62
R-R 153
neuro 459
TLA 32
HGBLR 406
MFC 331
ixazomib 87
XO 76
PD2 426
co-mutations 7
LUAC 73
EGFRa 96
ex19del 223
SqNSCLC 453
SACTx 333
IMCgp100 206
MTBS 360
Invasion 1
daytime 61
mtDNA 203
MYL5 203
MYH8 203
PBTC 399
CBM 123
OXA-PNP 203
circadian 266
rhythm 266
anamorelin 15
balm 266
Patch 266
BCRL 298
ADB 393
LR-AML 18
splenectomy 220
HPV-SMN 220
CUDC-907 234
MR-HIFU 324
dedifferentiated 110
MRCL 110
D842V 86
0630 137
CCT 108
IG-IMRT 335
BGJ 276
ULMs 296
tazemetostat 183
HGESS 224
AIDS-KS 39
CKS 39
AMC 364
PBS 32
non-NSCLC 343
Oregon 27
BCR-ABL 236
Unfortunately 278
Special 463
bioavailability 326
translated 495
exams 317
compromise 29
eliminate 155
HER21 245
overtreatment 195
science 242
Melvin 384
Routine 292
alternate 324
Benefits 200
identifiable 97
vast 13
extramedullary 296
delivers 321
27.6 51
15.1 51
rea 176
stitute 60
apies 80
remarkably 32
gpNMB 94
Cance 94
glycoprotein 321
iva 176
M1c 405
NCCTG 447
x3 432
IIA 405
reversed 275
WSG 168
94.6% 405
raw 317
hypophysitis 272
14.8% 173
34.2% 405
505 286
pipeline 109
priori 97
modules 203
backbone 281
438 186
43.3 51
declared 101
pre-defined 341
nCounter 96
93.3% 405
97.5% 405
conservation 168
Dana 27
merits 80
520 204
439 191
513 286
mandated 4
2.00 389
PgR 132
Supported 140
825 335
q3wks 276
hand 271
cal 384
14.1% 173
post-NAC 22
cleared 268
437 455
cutoffs 430
Full 270
465 286
CIOFF 395
OFR 395
estradiol 130
DRFS 307
2.24 135
Copy 109
QC 107
CNV 109
525 218
doctor 461
non-adherent 393
1.71 135
2.34 135
Tata 384
TMC 193
Mumbai 384
E5194 289
metaplastic 199
29.7% 405
advised 197
qualify 399
histopathological 462
definitions 209
van 282
Vienna 384
Austria 384
76.5% 405
DDFS 307
congestive 272
mendations 13
Funded 453
Davidoff 4
Aviv 2
EET 388
Variable 39
1.98 313
ORs 11
participant 265
Almost 13
denosumab 488
55.4% 405
estimating 249
371 146
556 286
tr 176
Dosing 276
surg 6
workflow 195
cN0 449
accelerate 242
15.6% 405
6.0% 173
cN 209
simplified 283
adjunct 420
limb 449
dramatically 74
sidered 271
Yat-sen 282
2.30 135
conclusions 358
Scott 470
Selected 117
Caucasians 174
route 22
cosmesis 449
hypofractionated 400
IORT 400
post-surgical 170
21.2% 173
8.8% 173
2.15 135
2.06 135
TBC 307
administering 41
8.7% 405
577 451
25.9% 173
EarlyRHigh 214
labeled 238
Cyclophosphamide 67
cellularity 399
non-responder 344
calculator 134
583 455
neutrophils 271
fat 203
Nacional 353
collect 298
biospecimen 160
urine 473
double-blinded 457
fashion 7
fibrillation 272
suffer 41
examines 196
needle 22
deficiencies 315
440 186
surrounding 399
delaying 65
enzymes 271
RPPA 96
Abemaciclib 130
4.0% 173
78.6% 438
Genentech 140
Stratified 217
48.6 277
io 94
neratinib 31
non-CNS 319
enter 349
Nicholas 60
IRF 101
Everolimus 306
da 94
ib 176
1.89 135
Alexandra 107
Co-primary 206
Roche 140
regulated 369
Joshua 107
Growth 370
instances 433
25.8% 187
preclinically 207
CLEOPATRA 130
discontinuing 178
multimodality 227
suppresses 322
Jose 130
cutpoint 430
FES 477
AC2013 163
7.2% 489
pocket 274
mbc 274
Mice 32
up-regulated 203
exceeds 285
Carlos 314
61.5% 405
ZW25 234
utilizes 89
zumab 176
Std 403
25.7 51
cyclin-dependent 130
0.059 277
54.5% 438
p-AR 132
TSC1 433
Activating 279
Is 292
64.7% 17
0.030 152
verse 446
discontinuations 271
cations 272
regulate 275
18.6 51
released 396
conclude 65
Le 290
Resistance 94
genotyped 179
fall 170
70.6% 405
applicable 356
implementing 193
NIH 453
retinal 272
anti-tumour 334
ˆo 290
conjunction 283
mammalian 275
sociation 258
588 408
Prophylactic 8
50.0 51
34.2 412
DRP 217
axial 381
WG 46
Patient-reported 159
au 61
real-life 356
ducted 149
alyzed 305
TA 317
substitution 13
21.2 379
fragments 364
1.59 135
0.056 152
STAT3-driven 239
seizure 272
diminished 236
ag 302
space 44
TFx 225
478 451
Exact 439
17.5% 173
well-established 169
nuclei 211
tran 315
ligation 96
Gh 174
proliferating 293
Ribociclib 324
dropout 325
later-line 130
BET 275
U3-1402 234
linker 38
formance 92
regi 35
preferentially 321
retention 341
CBZ 479
CLIPT 89
Continuous 90
pack 20
retreated 421
priming 238
acts 275
RAD50 483
RAD51 483
heritable 97
EPCAM 361
497 218
surgeries 391
agree 395
PCP 461
8.6% 438
hospital-based 229
nurse 193
468 455
Maryland 470
HRHPV 133
72.4% 405
26.5% 459
34.5% 492
suspicious 380
incidental 491
perception 197
geographically 265
15.9% 173
Next-generation 21
ACMG 97
penetrance 97
off-target 369
suc 22
PathoMAN 97
classifications 182
translocations 237
Brown 27
college 201
Interventions 123
Presbyterian 230
ascertainment 10
Aberrant 275
adds 327
13.8% 173
13.1% 489
time-dependent 217
UAT 385
flushing 355
investment 46
Fewer 405
comfortable 461
intraepithelial 293
Considering 418
E1L3N 49
patient-provider 201
Jersey 230
evalu 244
educated 201
newsprint 194
6.3% 173
Providers 162
25.9 51
LDCT 244
Diabetes 102
ies 176
urban 160
discrepancies 258
ade 424
Weekly 187
29.7 51
30.0 51
hibition 322
normalization 341
causal 258
informatics 265
Death 162
734 429
P-Value 277
Nutritional 392
CONUT 392
dl 364
cholesterol 300
western 419
symp 298
school 201
protective 258
analyse 161
globally 185
YA 298
Increasing 159
ring 424
Brazilian 160
Edward 107
Whites 174
Genes 343
Taken 267
contributes 74
Adenocarcinoma 386
tanning 258
DSE 10
travel 13
Decision 46
Poisson 439
498 191
ENGAGE 10
regulators 369
QI 160
multiforme 437
glio 166
suggestive 299
logic 376
stimulation 322
Vemurafenib 184
NCT02228369 31
prevents 322
Friday 463
Marseille 290
cranial 380
LTS 437
SVM 235
maps 317
RNA-Seq 96
RNA-sequencing 316
NTRK2 273
EML4 342
geometric 276
rodent 419
17.9 412
67.3% 478
30.6% 223
CTRI 335
depend 322
PubMed 246
generating 242
reimbursed 274
tandem 268
ependymoma 301
input 265
CpG 437
TERTp 182
23.3% 431
VFW 34
rear 237
Kaiser 2
creating 238
rolling 234
slower 495
iii 426
431 218
Plerixafor 79
ICT-121 368
a-SHH 110
p-SHH 110
Carlo 285
27.7% 173
WT2725 234
coronary 102
Eighty 128
adjust 217
NBM 288
deeper 245
quired 497
PIK3R1 7
uPR 333
regulates 275
PTCL 153
myalgia 271
25.0% 438
Investigation 245
0.0019 152
MTT 51
AZD3965 467
engage 461
potentiates 336
Ph1 284
pan 440
distributions 439
RECIST1 292
CLR 401
3000 318
1800 283
706 1
thrombosis 459
TCC 467
assembly 275
representation 174
Prolonged 366
myositis 272
fibrosis 449
Another 344
NACD 246
plateau 358
zation 260
Pulmonary 8
Flow 293
LFTs 271
extraction 265
c-MET 106
pharma 349
75.0% 405
permanent 272
Oncologia 353
leucopenia 26
M3814 496
cleavage 419
icities 324
Moderate 483
non-hematologic 272
MedImmune 38
DPD 402
L792 278
PTC596 467
EC1456 234
RP2 324
Durable 296
gas 176
Mt 252
Radiographic 355
anoma 207
Recommended 324
Oklahoma 27
ETC-159 467
Kidney 348
cancer-specific 461
inherent 369
MBC-11 234
actively 396
taladegib 324
qualitative 265
lapsed 178
RF 52
AbbVie 63
RNR 467
synergistically 322
siRNA 419
mab 349
ATR 315
ABT-888 346
master 369
sor 333
NY-ESO-1c259T 310
anti-PDL1 238
secreted 345
myeloid-derived 322
bb2121 368
MRD-negative 411
curred 421
BGB-A317 334
BGB-290 467
Urothelial 386
Taipei 60
manufactured 473
immune-mediated 322
log2 293
optimization 396
ALB 403
LM2 47
kinetic 341
quenced 109
Neuroendocrine 466
Malignant 120
21.6 379
Autologous 368
cold 484
thymoma 56
anti-programmed 373
resting 203
CD28 321
recovered 310
immunotherapeutic 239
C-reactive 364
Aza 26
nonsynonymous 415
cobimetinib 184
CCTG 453
NCT01772004 340
Brien 183
pl 276
COPD 194
ELISPOT 473
JS001 334
T-ex 32
Site 250
revolutionized 373
COM701 322
computational 242
disrupts 275
angiosarcoma 110
HPV-negative 434
episode 272
PG545 334
allergic 272
abscopal 334
Lauren 470
spreading 111
Buffalo 107
Levine 2
MAGE-A10 321
duced 152
phagocytosis 322
TAK-659 496
CX-072 234
typing 235
combine 242
consortium 487
icalTrials 140
0.031 152
attempt 285
cetux 428
CMS3 493
Nanostring 415
12.8% 173
emesis 26
SAR 36
analytical 235
Checkmate 409
RFA 435
HRS 1
CRM 1
dictive 341
thromboembolic 272
arterial 459
PFS1 51
24.0 51
Hamburg 384
thromboembolism 459
mesenteric 251
associates 111
opposed 65
Price 274
caspase 419
Immunoscore 293
megabase 343
Smith 107
433 45
5.7% 489
PTB 297
Vmax 412
unresected 423
Resection 449
CapOx 137
Agilent 96
termediate 431
vendor 150
on-study 26
SOR 448
plots 430
032 340
nr 328
10.9% 173
chemother 164
pre-chemotherapy 341
gen 278
Gastric 384
How 292
Beaumont 27
pN2 1
TABLE 152
Infection 390
sions 97
favourable 69
Measures 393
ATs 325
ian 176
d1-3 283
Amcasertib 496
PSM 393
patient-specific 474
somatostatin 477
PQI 458
SREs 390
7.3% 48
CA-125 206
MOS 215
58.3% 406
69.5 51
nal-IRI 443
CAC 229
DAC 141
58.8% 173
Nab-P 440
542 218
sun 144
54.2 51
MMR-D 111
cystectomy 6
VAS 138
DCO 333
Insitute 226
instillation 352
UCC 423
2.41 135
HG-RFS 426
HD-CTx 88
TDM 401
NSGCT 297
averaged 265
CM082 284
DOT 141
metric 158
T3a 431
fusion-positive 207
clinical-genomic 235
chemotherapy-naive 479
GETUG 408
DTX 170
REO 479
Ra223 14
aggressiveness 195
PCWG 43
TTh 488
covered 265
PI-RADS 317
ODM-201 497
8.0% 173
ENGOT 169
vulvar 434
SOLO2 346
surance 17
Letrozol 426
Niraparib 346
IVB 423
BSA 17
SCCC 416
Smoking 194
England 4
ICR 101
HGSC 374
FRa 382
soravtansine 346
S6 275
readmission 17
388 171
OECG 170
LN-ve 425
GEN-1 41
LAG-3 472
Leuven 107
IG 266
anticoagulation 484
POST 354
nasopharynx 20
PTC 184
pharynx 20
NF 406
personalised 83
Milwaukee 153
GFR 194
sdCRT 65
INO-3112 472
E1308 266
FACT-HN 266
ommended 193
insurers 274
establishing 242
manufacturer 17
choosing 46
reliability 46
billing 46
oncolytics 274
MACRA 46
binomial 439
assistance 461
449 286
weekend 159
Transplant 24
disapproval 213
LOI 213
QL2 210
budget 12
Pharmacy 27
myelofibrosis 63
blast 77
ITD 236
Enasidenib 63
mIDH2 241
enasidenib 296
AT1413 321
guadecitabine 19
mRUNX1 236
trisomy 64
siblings 17
IMFS 21
BMBL 77
Rigo 264
VOEs 254
RICOVER-60 19
entospletinib 496
iFCG 19
BCL 153
DH 62
ASN002 496
SA6RT 215
TLG 317
IGH 62
px 281
MRG-106 334
mech 278
elotuzumab 87
CRD 411
Ixz 87
apixaban 41
acupuncture 61
DAR 12
partner 369
dFLC 128
CIF 321
AFM26 321
NK-cell 322
VP 137
non-epithelioid 424
MSK 21
ALK-positive 58
CxT 307
LUAD 374
class-I 297
TC0 73
METdel14 106
TBP 340
KL 73
Ex20ins 278
p-Akt 132
YES1 273
BCC 244
ALTA 58
RET-rearranged 279
dNLR 364
thickness 1
REGN2810 334
sSCC 434
APD 308
SSM 111
NNS 121
aerobic 266
LEC 17
non-L 17
seniors 421
PIM 74
waitlist 266
AMI 102
NoA 399
SBI 13
ONS 266
SPEP 266
Lifetime 263
TGN 311
EoI 387
desmoid 290
fosaprepitant 41
LTLD 324
soft-tissue 290
REGO 284
TVS 288
Gb 333
LGESS 224
DMA 141
nSLN 209
exoNA 170
QCCs 399
CCS1477 497
p300 497
CBP 497
PCC 316
CA20 430
TK216 234
powerful 155
dramatic 245
numerous 245
dimer 419
bind 369
regulating 369
persons 274
Palo 2
Alto 2
achievement 269
lives 461
goals 461
Plenary 476
rard 290
fast 361
Erin 2
Utilization 160
lineage 316
reinfusion 310
chills 26
53.5 51
Burris 60
transmembrane 321
int 176
lat 176
lyses 95
850 401
Veneto 224
matter 124
debate 384
pN0 449
PAI-1 399
15.3% 48
Adaptive 72
Tamoxifen 130
unsupervised 235
ejection 251
systolic 251
resu 176
lts 176
Mastectomy 168
comprise 4
attending 162
endorsed 13
CT-P6 444
46.8% 405
9.0% 173
53.2 277
35.3 277
31.5 51
38.8 51
33.1 51
86.3 277
509 218
Then 187
bpCR 444
per-protocol 101
51.7% 405
35.8% 405
Distribution 174
excised 168
exemestane 306
3600 283
64.3% 405
88.9% 438
516 397
dose-dense 428
concomitantly 428
33.8% 405
48.3% 405
47.6% 405
14.6% 173
Ulsan 282
Asan 282
83.7% 405
V4 192
marginally 403
Maastricht 282
SABCS 356
definite 395
73.1% 405
Visual 295
Lastly 299
Odette 375
Better 375
009 189
Size 431
23.2 277
endogenous 322
CD45 293
KS 2
justify 74
531 286
non-persistence 159
538 286
concerned 201
3.26 135
cT4 54
534 162
ACRIN 453
avoided 449
AdjCT 214
Neither 211
537 122
539 122
ILC 196
Log-Rank 217
2.23 135
discordance 201
16.9 51
546 122
Chi-squared 439
59.1 51
70.5% 1
Individualized 245
FECD 98
Baker 375
943 286
688 39
63.9 277
26.8 277
Academic 384
fractures 390
Wayne 107
574 286
Controlling 1
552 218
21.0 51
spine 488
553 198
carefully 484
Scotland 4
22.4% 173
avoiding 29
555 45
ical 476
postoperatively 449
Modified 161
cT3 335
gery 282
width 168
dergoing 10
omitting 90
cross-validation 235
backward 439
preoperatively 395
75.0 277
60.0 277
raising 326
scenario 160
appearance 34
565 286
Baylor 470
defect 315
objectively 195
HF 220
18.3% 39
3.35 135
40.9 51
26.6 51
573 45
83.3% 215
575 283
four-gene 235
576 185
istered 276
454 286
31.1% 405
striking 97
chi-squared 439
re-biopsy 209
stantial 50
shock 271
Dublin 282
TCHL 22
libraries 96
VAT 209
Forty-six 128
585 218
23.5% 405
epidemiologic 74
Min 384
BRCA-mutated 414
Ax 449
acti 322
potently 275
MICRA 392
Improvements 161
Epidermal 370
RCB 214
12.4% 223
adenosine 345
21.3% 48
22.9% 438
post-menopausal 130
additionally 97
Perez 2
ISH 49
paronychia 26
King 466
dimension 92
lated 265
KEYNOTE-086 340
Univers 94
Evaluating 146
justed 439
velopment 346
Victoria 107
subclones 182
tracking 182
tissue-based 374
termed 316
suppressed 275
suffered 380
PHEREXA 130
HCP 12
HRa 11
Wong 2
Centers 162
CD274 361
kinome 396
multiplexed 96
beads 321
SYK 469
reclassified 1
person 490
elucidated 369
experiments 207
H1047R 433
Pneumonitis 26
translation 321
Marital 194
46.4 277
78.6 277
interplay 369
22.0 51
26.4 51
Engl 105
Protein 364
p-4EBP1 132
ERBB3 273
non-measurable 319
Nottingham 466
462 455
AMBRA 356
VTB 356
cate 141
sequent 356
So 356
Regarding 395
11.9% 438
collects 298
successive 324
62.0 25
Non 438
Estrogen 388
statements 13
42.4% 405
27.8% 277
Recommendations 13
Experience 375
non-interventional 384
Universitatsklinikum 384
Erlangen 384
experts 193
shRNA 419
JUN 361
72.5% 438
incorporation 155
94.5% 405
79.5% 405
Subtype 62
rently 242
Petah 4
Tikva 4
stored 83
landscapes 111
Rash 26
collagen 364
2.55 135
Greenville 27
advantages 239
Q9W 150
Christopher 27
Cruz 53
timepoints 341
introduced 27
Cell-free 374
infrequent 299
63.9% 48
29.3 277
TTK 275
Mesenchymal 214
Sacramento 2
428 455
Eth 174
exerts 207
OCT2016 333
NCT02178722 33
OVCA 357
CTCAEv4 329
RECISTv1 329
apeutic 245
dose-expansion 284
potency 207
creasing 102
maintaining 296
POD 82
BRD4 419
icity 16
TAK-228 130
Garcia 169
mens 87
Bristol 466
end-points 206
Union 282
Apatinib 469
VEGFR-2 469
HLA-A2 368
Paired 473
Discovery 318
Mutated 7
Continued 375
Are 197
metrial 424
telephone 160
473 45
worry 195
colonoscopy 258
cision 393
modify 258
germ-line 316
variance 439
regularly 298
middle 219
practical 195
Significance 64
lly 94
iversity 94
commonest 459
smear 197
Pap 197
NMSC 476
Vitamin 476
Chan 470
13.4% 489
causative 483
17.9% 489
Guardant360 109
PVs 483
cover 160
veillance 197
KCRG 201
0.040 313
10.4% 489
sharing 274
annotated 109
lin 176
understudied 74
Sutton 466
pericardial 459
34.1% 173
height 258
designated 237
counting 97
diagnostics 374
Preventive 197
actionability 195
2500 109
geted 242
Laboratories 53
non-AJ 10
18.7% 489
non-coding 361
SRC 275
IMT 373
statins 197
Initiative 53
Hazards 430
digestive 459
iodine 6
heavy 299
NCI-sponsored 453
t-tests 439
NSDBC 395
27.3 51
23.9 51
dys 61
Brunswick 230
sectional 298
44.8% 405
epidemiological 244
2.02 135
recalled 393
fair 200
existence 299
fear 13
28.3 277
metabolomics 396
non-carriers 201
cu 220
veterans 162
Affairs 27
765 490
replacement 88
hysterectomy 395
menopause 201
NHIS 162
9.5% 173
Na 27
Standardized 162
1.80 313
Nijmegen 2
hema 124
Lin 470
36.7% 405
30.8% 173
pharmDx 49
moderately 211
smoker 492
closer 393
53.5% 173
Self-reported 197
regret 393
Percentage 395
92.3% 478
726 286
pleted 350
el 271
VHVT 265
position 297
precisely 374
oncologist-led 10
accruing 457
professionals 160
activator 275
synergism 207
mucosa 399
teams 160
environmental 120
Cen 94
blastoma 183
distinguishing 155
Potentially 213
multi-arm 457
tases 294
Mets 188
DIPG 436
rollment 349
33.5 412
underrepresented 246
methyltransferase 437
radiographically 344
radiomic 317
perfusion 317
prioritized 242
codeletion 320
KIAA1549-BRAF 493
Ta 100
Max 250
hindered 34
Samuel 107
overcomes 369
MRIs 161
11.6% 438
rehabilitation 158
Timothy 447
Severe 134
craniospinal 18
difficulty 393
24.1% 73
276 185
delivering 238
contrast-enhanced 34
FLAIR 34
oncometabolite 241
tend 296
Newly 336
vasculature 112
two-part 234
nostic 141
Dresden 384
peri 381
spinal 400
architecture 182
Permanente 162
Individual 439
marginal 153
synthesized 96
0.0006 313
historically 245
chemo-RT 335
Cedars-Sinai 2
hallmark 376
triggered 0
dition 29
loaded 321
construct 38
newly-diagnosed 336
failures 13
disseminated 380
Fu 283
Johnson 60
confers 141
U. 474
Planning 162
735 20
BMs 380
ological 399
plification 372
TVB-2640 325
promoted 275
VAL-083 437
alkylating 207
mission 296
produces 373
interfere 65
independence 77
maculopapular 26
folate 234
BI 467
basket 496
IMWG 329
ALRN-6924 234
acneiform 271
START 314
mately 326
Infusion 334
phenomenon 299
EGFR-mutated 278
Personalized 27
cognate 238
unstructured 193
hx 492
TRC102 336
SDs 40
PT-112 234
First-in-human 318
MCLA-128 234
mAbs 373
sensory 271
readers 393
perfect 393
Philip 107
SCB01A 234
electrolyte 271
Landmark 217
enrollees 274
AstraZeneca 453
money 13
Event 220
743 409
TAS-116 496
FIH 234
NKTR-214 472
immunophenotyping 473
duct 199
harbouring 278
reconstruction 449
TCB 38
intra-tumoral 32
0.052 313
Tmax 326
Lim 282
D1-3 283
tendency 37
LMP776 324
Helen 2
biochemically 477
tinuation 26
PlGF 458
Irinotecan 283
SN38 179
inverse 258
VKORC1 125
pharmacogenomic 141
C797 278
PLLC 60
BRAFV600-mutant 184
CC-90003 496
eFT508 467
mRNAs 32
CVM-1118 496
capsules 346
department 158
FGFRamp 372
O. 107
colony 419
DRD2 467
ARID2 273
SMARCB1 273
claim 162
Robust 419
tx-related 26
Promising 334
presumed 213
Etoposide 276
COH29 349
pool 311
MW 458
histologically-confirmed 42
reactivation 275
posed 220
Chk1 275
jectives 349
nanoparticle 234
AZD2811 234
integrity 170
DL3 276
Del 107
TMEM 322
Tie2 112
formulated 321
native 419
Cis 35
TI 77
Onc 105
oncogenesis 275
clude 329
exclusively 275
uniquely 74
ETCTN 213
mis 258
CFI 425
AUC0-12h 324
substudies 83
evi 326
Frank 384
efficacy-evaluable 333
diameters 344
retreatment 255
transfected 321
CARTmeso 473
extensively 111
0.036 313
machinery 369
CD19-specific 310
patho 255
63.6% 82
0.0016 73
Axi-cel 368
culture 321
Shah 60
turnaround 83
post-platinum 333
0.055 152
G12C 475
ICONIC 5
pPROG 22
0.0011 313
19.2 51
878 204
24.3 51
trees 439
anti-CTLA4 472
relief 77
editing 369
Cas9 369
Absolute 170
TAMs 299
Activation 373
IPA 322
26.1% 299
Bendell 60
Karen 2
NCT02155647 340
oligoclonal 472
SMART 244
Ryan 107
Thirty-four 405
40.9% 48
39.7 277
FACS 473
MC38 32
non-CRC 333
multimodal 484
AGEN1884 234
sequelae 484
TrAEs 271
hypertriglyceridemia 26
x106 67
muscle-invasive 199
NKG2D 321
monocyte 473
apheresis 67
MAGE 321
Sandra 107
eat 238
employing 90
tered 496
non-progression 255
Eur 464
intra-T 432
Ti-061 234
ERY974 234
GSK3359609 349
Log-rank 217
32.6 277
histo 399
fruquintinib 58
25.3 277
27.8 51
classifiers 361
16.6% 48
tivariate 141
ventional 155
post-op 266
ct 374
requirement 77
inputs 265
avg 439
indicators 159
existed 141
reviewers 9
non-resectable 423
Alterations 7
rely 315
TRIBE 402
STD 11
Technologies 96
Ox 402
2.14 135
Hamburg-Eppendorf 384
gastro 423
pe 310
post-hoc 98
Regimens 164
resumed 421
chemorefractory 447
trimodality 335
Australian 162
Rectal 459
in-hospital 359
uated 287
peritoneum 385
25.2 277
10.3% 173
ations 493
ANGIOPREDICT 235
Unsupervised 235
965 162
CRLM 435
tection 83
2.12 135
3.42 135
meEGFR-CTCs 170
Caroline 290
1.56 135
S492R 279
finished 137
portant 399
14.9% 313
curatively 423
clinico 297
Digital 83
BBI608 496
WNT 275
differs 246
NCTN 453
DW-MRI 435
extrahepatic 424
Deaths 48
16.5% 478
lenvatinib 448
uHCC 448
57.1% 48
cyc 176
Follow 411
HA-High 291
adenocar 424
cinoma 424
gemcitabine-based 35
Arizona 226
H0 325
XP 428
Belfast 466
TRG 430
savolitinib 35
umbrella 453
0.058 313
Colorado 2
Electronic 160
Eso 405
mediastinum 199
7.0% 173
Nationwide 27
one-cycle 335
IVA 6
AJCC-N 209
instrument 295
39.3 51
24.5% 438
HFS 271
12.7% 173
15.7% 405
ineligibility 394
Arm3 405
amol 81
1991 39
cytidine 207
ERBB 273
amplicon 109
TMBH 7
GBq 284
SUVave 430
TTSRE 398
utilize 160
Palliative 158
mPC 105
46.4% 478
neutrophil-to-lymphocyte 364
MVT-5873 436
Groups 429
Manchester 466
life-years 12
probabilistic 12
696 246
760 17
BMS-986016 340
Nature 315
uation 329
loads 316
Relapses 296
2.8% 173
31.2% 39
Gary 107
Investigator-assessed 333
B-701 144
2.93 135
ICC 393
Function 295
RX-3117 469
DOCE 440
Myeloid 185
G-MDSC 293
Transplantation 2
high-intensity 159
HIT 41
Responders 313
CUI 152
pair 109
UNL 364
shared-care 266
boundary 394
Heng 141
LTR 499
Marker 293
infiltrated 293
maximize 195
TCI 142
PSCC 6
associ 369
Paolo 224
Abiraterone 479
Abi 479
Gal 479
Enz 479
CYP17 207
1022 268
Grande 479
tomatic 294
computer 108
BST 14
2.96 135
viscera 399
AAP 479
retinoblastoma 290
small-molecule 469
ME 282
ASN001 417
sip-T 322
hormone-sensitive 477
DB 26
spent 13
filled 162
AR-Vs 170
Adjusting 194
OM 431
Increase 158
x4 35
UR 156
fractionation 308
AOC 6
unplanned 298
GEICO 353
ddTC 214
OC-NS 414
Markov 12
Pro 43
Platinum-based 164
stated 13
Two-year 286
AXL 469
SER 433
GOG 346
30.2 412
Florence 169
slight 102
Quisinostat 346
LGSOC 414
BRCA-like 483
mirvetuximab 346
FORWARD 453
MMMT-E 169
MMMT-O 155
HEALTHG 170
Grp 425
Alexandre 470
Da 169
42.5% 1
EEC 491
LIR 430
IFR 465
Maximum 276
intensity-modulated 335
III-IVB 335
in-transit 380
pharyngeal 434
50.5% 359
TIW 276
Cost-effectiveness 146
stroke 102
non-oropharyngeal 434
PBL 473
DRB1 189
monitors 195
rdCRT 65
eating 266
advanced-stage 229
MKI 298
DAB 496
CTM 193
Navya 193
Pp 158
PpChronic 158
bankruptcy 393
Individuals 162
Important 200
code-based 194
Affordable 274
pricing 46
069 308
SPS 265
Uninsured 17
African-Americans 174
readmissions 17
specialist 461
saved 12
averaging 13
Payment 274
donate 13
ACA-DCE 17
decedents 461
wearable 210
curability 195
transplants 24
FIM 158
ESBC 156
attempting 395
LOIs 213
Top 46
GoC 461
end-of 158
polypharmacy 74
QCDR 193
vial 46
Smaller 258
expenditures 274
DFCI 242
materials 13
JAK 469
SRSF2 64
SF3B1 241
ozogamicin 63
alloSCT 24
AOEs 254
mini-hyper-CVD 63
HCVAD 19
MRD-ve 236
azacytidine 63
DAC10 236
Ida 19
myeloid-T 316
depleted 419
tervention 266
myeloproliferative 64
lower-risk 64
MPN-U 64
Axl 419
LCH 74
iNHL 281
TTNT 411
Bcl-2 275
AutoHCT 281
MRD-neg 77
Brentuximab 296
Relapsed 153
WB-DWI 317
HD-MTX 67
Copanlisib 153
copanlisib 153
MPV 281
Comparative 279
MA-RT 215
Severity 295
LPL 153
eNDMM 19
anti-MM 322
maint 94
Organ 71
II-IIIA 278
sBM 137
PFS12w 325
ONSCLC 229
IIS 293
wedge 54
gDNA 109
OAK 340
ED-SCLC 423
EML4-ALK 343
EGFR-mt 7
Ex20Ins 278
mEGFR 278
Afa 278
post-progression 426
sub-study 453
GNE 223
HER2-mutant 278
Ctroughfirst-dose 276
Worst 295
CSCC 314
BREAK-3 47
dacarbazine 276
laBCC 354
SD-101 334
NAT 360
cuAEs 190
delirium 159
PTSD 61
URCC 156
IPC 17
osteoporotic 162
SCPs 461
4.55% 218
loneliness 123
BDI 123
calorie 203
NRS 295
Hosmer 134
painful 298
GRAN 41
connectivity 123
minocycline 266
dryness 61
dyspareunia 61
CAGE-AID 393
timeliness 158
HBC 247
PanC 258
Str 258
BRAF-WT 493
AAML1031 18
SMN 102
DXRZ 18
DOXO 18
STET 227
CYC 18
Aflac-AML 18
MIBG 381
RONI 319
L-sarcomas 427
BLU-285 469
SO 39
CXR 108
GKS 335
HOTAIR 361
MPT 381
PDGFA 430
CTC-status 141
ARV 361
CK19 209
Cssmin 225
TGFbR3 112
OWBC 214
ACE 109
PGL 316
CIN25 430
Lum 132
WINTHER 242
sirolimus 496
helped 245
platelet-derived 370
Brenner 470
chose 344
child 74
substitute 13
radiation-related 390
stimulated 238
ultimate 130
arising 54
spite 65
develops 31
ensuring 46
evolved 21
advocacy 160
conversations 461
prevented 300
Paris-Sud 290
economical 265
Community 27
appropriately 269
60.9 51
Numerous 239
Observed 121
D28 310
fell 310
tumo 94
catabolism 32
kynurenine 32
pharmacody 349
namics 349
ton 94
eva 176
Neu-Isenburg 384
Oncologico 224
SOLE 130
cancer-free 135
PlanB 168
der 384
506 455
nations 422
task 123
re-excision 449
publication 9
37.6 51
47.1 277
47.7 277
42.0% 405
micrometastasis 449
BCSS 293
T1a 431
Farber 27
choices 356
604 204
CALOR 168
effec 272
UP 358
tistically 358
R-C 425
C-high 405
G-high 137
Compliance 138
13.7% 173
14.2% 173
518 286
pac 428
16.4% 405
53.2% 425
769 286
McGill 375
487 397
737 286
486 45
Pw 425
grants 453
80.8% 137
94.4% 405
ICGC 235
FGFR4 372
AKT2 7
passed 223
nursing 17
A-based 29
adherent 201
feel 393
Living 295
Fertility 230
Yoga 138
605 198
terioration 138
528 204
ODC 289
Lymphocyte 399
LPBC 388
89.6% 307
post-diagnosis 99
ini 446
72.1% 405
19.1% 173
35.2% 173
58.4% 1
76.6% 1
38.2% 405
multiparameter 228
Scores 395
T1N0 229
chemical 275
Christian 384
27.5% 438
77.3% 1
670 218
Miller 107
sizable 155
ddAC 428
cologists 160
MOs 13
543 286
24.0% 1
21.1% 438
confounded 287
Proportions 395
57.1 51
27.2 51
26.3 51
548 171
ODX 430
prohibitive 90
extending 65
non-statistically 102
Females 194
protect 385
lumbar 488
femoral 488
Sylvester 2
47.3% 223
55.7% 39
exploit 239
Records 162
regime 242
559 286
lizumab 176
ele 271
Kliniken 384
harvested 22
sity 282
24.4 277
justified 358
mac 293
ypN 209
ycT 209
2.80 135
Specificity 209
53.6 405
55.9 277
views 160
vestigated 322
567 218
compression 435
easy 195
MRM 71
15.5% 403
44.1% 204
dependently 430
572 204
dense 80
q2wk 432
lurbinectedin 422
24.3% 173
20.4% 438
Lurbinectedin 346
59.3% 405
77.4% 405
platinums 164
Julia 384
579 45
collectively 200
intriguing 242
Missing 128
TCH 22
transcriptomic 316
fibroblasts 322
Obesity 392
VAT-HU 430
aVAT 430
tertile 430
AC-T 405
Enfermedades 353
Pathological 395
ence 74
non-users 465
Questionnaires 138
injectable 82
yearly 9
JAMA 105
boundaries 394
FNA 22
assign 195
similarities 374
compromised 315
CCCA 325
goserelin 176
C1D15 276
Oncolog 353
ıa 353
unprecedented 422
two-arm 457
Burden 295
446 186
45.1% 204
PALOMA-1 306
47.8 51
34.5 51
27.4 51
Sponsor 140
53.7 389
Hypertension 26
Hepatic 459
idence 176
comb 176
tes 94
1006 95
complexity 302
tas 94
non-target 344
gBRCA1 483
exhibiting 82
Adams 107
EXE 306
1011 67
Intracranial 294
20.1% 438
RAD1901 130
modulating 275
tential 275
31.7% 173
InVision 83
tagged-amplicon 83
Clonal 182
undertook 374
FoundationACT 109
Ben 60
Clearance 458
Health-related 33
668 291
NCT01958021 306
32.8 51
483 225
28.3% 173
Hershey 470
Eribulin 428
Yokohama 282
MIB 419
upregulates 322
anti-diabetic 41
reflex 163
HER2-equivocal 163
HDHP 274
followup 128
socio 194
residence 194
co-cultured 32
rejected 325
restored 419
transgenic 207
bocytopenia 26
52.3% 201
48.4 277
45.7 277
775 174
consequence 396
neutropenic 272
666 188
444 186
3.15 313
leukocytes 32
tmen 176
functionally 361
terized 361
KCSG 384
Substantial 272
liminary 334
drug-drug 326
Infections 26
100.0% 401
45.0% 48
22.7 277
complicated 371
Inhibitors 315
describing 396
79.3% 438
29.3% 438
Lurie 107
Feinberg 107
exposure-response 140
MBCP 130
Haematology 466
DhExe 179
D29 179
steady-state 179
Frequencies 179
labelled 44
rd-line 333
34.9% 1
8.1% 173
Huang 60
reviews 9
agencies 46
Company 140
previously-treated 453
Consequently 396
Subsequently 96
Albert 169
isoforms 275
multi-cohort 457
obvious 326
biosynthesis 275
sys 477
Let 458
LLOQ 458
ordinal 341
MCF7 132
tenance 176
ight 476
quence 249
36.1 277
32.4 51
41.2 277
39.0 51
incorporate 160
14.7% 173
Herlev 60
bining 141
mated 439
App 456
Unk 71
AH 405
5.78 389
validating 418
benchmarks 37
Trop2e 132
IMMU-132 345
trop2e 132
Kruskal-Wallis 439
stem-cell 281
chemosensitive 18
1994 117
well-defined 155
733 429
sessments 90
Beva 155
634 109
ABCB1 425
0.065 313
pathogenicity 109
nsSNP 273
cir 83
C1M 364
C4M 364
Pro-C3 364
2.42 135
1.67 135
BBI-608 28
nested 263
preparation 393
0.037 389
MpBC 374
genomes 109
burdens 182
discover 374
chemotherapy-resistant 374
draw 265
universally 302
IIIB-IV 42
Mortality 270
nucleoside 314
50.1% 405
TMAs 49
B-cells 473
clustered 235
widowed 17
delineate 399
Hos 169
competition 46
Sevi 130
sented 394
Unconfirmed 48
posterior 61
effi 422
cacy 422
pharmacoki 349
FUL 130
Locally 282
Intervention 138
prove 242
standards 265
bromodomain 497
PARP-1 315
UGT1A1 216
randomisation 206
Zhu 282
Monotherapy 373
tational 415
proach 285
Lineberger 2
ExAC 97
827 45
path 182
2.88 135
30.8 412
in-person 10
shortage 160
non-white 152
affiliated 162
17.3% 173
sedentary 258
007 201
BIC 195
appointment 13
community-based 160
22.6 51
High-risk 359
Variation 39
70.8% 17
47.2% 17
85.3% 395
water 258
dur 368
80.6% 39
Deleterious 483
SMARCA4 273
63.6 405
oncogenes 273
kindreds 491
numeracy 393
definitively 164
disagreement 393
interrogated 97
web-based 195
large-scale 155
hip 488
evant 249
Bank 96
Reference 51
racially 195
802 286
Genomics 156
PMID 109
NGS-based 109
Faculty 282
Expanded 109
stratifying 195
ranked 235
well-characterized 21
Syndrome 21
first-degree 201
named 374
poses 245
bioinformatic 97
plications 223
teraction 369
PAX8 316
founder 7
held 13
invasiveness 34
mark 201
BRCA-associated 201
61.3% 405
77.1% 201
Se 156
federal 461
SDBC 395
CH 201
21.3 51
451 270
29.9 51
heard 201
53.3% 173
Minnesota 160
nurses 13
33.0 51
FSH 458
liferation 275
disagreed 13
element 375
Communication 461
Ptrend 403
Nepal 197
organized 160
cancerous 182
1975 244
susceptible 315
coaching 461
autosomal 97
fumarate 369
volunteers 311
exclude 242
68.5 51
Fukuoka 282
low-PNI 307
PPI 194
reflux 459
GERD 390
aspiration 22
flammation 369
Nicole 27
dividuals 21
12.3% 173
Education 282
birth 265
57.9% 385
person-years 102
adulthood 298
YAs 490
gastro-intestinal 110
tological 462
properly 160
epidemiology 246
Centro 353
Raza 169
93.9% 152
morbidities 194
co-morbidities 162
Multidimensional 295
sured 203
66.9% 201
single-nucleotide 109
Whi 174
15.1% 173
38.1% 438
27.9% 173
Supreme 21
Court 21
chi 439
notes 193
Mixed 270
spectroscopy 161
sults 195
scope 244
Barriers 461
expectations 195
screener 10
summarize 265
office 13
terventions 160
dissemination 74
structures 369
vaccinations 347
Unfavorable 51
stimulating 369
vac 176
seizures 14
reactive 321
toxin 38
toma 94
TKI-na 31
Drug-related 421
tracranial 380
IDD 324
Wee1 275
non-enhancing 34
Oscar 290
principle 419
469 286
CED 238
non-progressive 366
4000 324
absorbed 326
dosimetry 477
zolomide 18
Timone 290
uncontrolled 336
perfor 250
mance 250
PsP 344
Remaining 344
http 319
receiver 430
physiological 419
50.8 51
Fusions 273
Aaron 2
evade 322
Twenty-four 82
endoglin 112
non-heme 26
incurred 158
CCF 266
oligodendroglioma 378
optimum 29
Bx 142
16.1% 438
Utilizing 54
Sick 263
intellectual 123
Hearing 123
verbal 123
HGG 199
glial 369
Ahmed 470
transiently 207
Ig 316
822 171
Gr2 26
46.7% 478
Tolerability 409
predictable 302
Wei 282
anatomical 381
discriminating 235
0.862 1
ferent 196
considerably 196
2.35 135
Percent 332
pre-surgical 497
partment 282
twenty 109
rangements 237
endothelium 369
proximity 96
PLA 321
TThP 324
vessels 317
Jeremy 107
attack 322
DKFZ 384
DMF 336
cyto 413
MIF 419
PDCLs 315
Src 275
Radiological 128
Beck 295
Simultaneous 60
gressed 340
Immunohistochemistry 22
tumor-derived 374
S4LC 288
ciations 439
craniotomy 128
recurring 237
Metastases 380
assurance 298
technical 195
progresses 242
Enrique 107
removal 287
HFSRT 42
afenib 275
Feasibility 484
hyperphosphatemia 271
larotrectinib 469
ONX-0801 234
AFR 234
overexpressing 234
894999 467
Georges 290
Q21 276
co-administration 67
pharmacological 495
thrombocy 26
topenia 26
permit 50
dose-proportional 326
Tucson 107
PF-06647263 234
Huntsman 53
anti-drug 341
monotherapies 207
10.6% 438
costly 46
Integrating 160
transporter 467
glycolysis 34
ICD 221
MEC 63
2.75 135
corticosteroid 484
agonistic 38
transitional 423
Reserve 226
dysphagia 26
040 409
nonlinear 341
NONMEM 285
Simulations 341
932 286
616 393
38.6 51
61.4% 405
distinction 393
chemically 267
Accurate 449
episodes 26
weakness 271
Sophie 290
MAD 324
NCT02490800 467
gardless 406
EF 201
Native 174
DS-7423 349
732 162
Countries 46
975 286
32.4% 173
timepoint 458
diary 266
Relationships 210
agency 46
INC 213
hos 158
Dyspnea 277
QOD 276
squa 199
radiologically 344
Red 353
70.0% 478
31.3% 173
OHOA 467
rHGG 284
Ras 275
TID 324
MLN8237 496
Totally 58
progenitor 369
expanded-access 409
Tufts 60
RECOURSE 277
idarubicin 19
sAML 236
GaPSMA 477
617 477
LuPSMA 477
avid 381
deceased 51
discon 26
H3 493
probes 235
Array 96
MBq 22
nomograms 115
NCT02087423 47
pan-HER 314
21.7% 173
ities 155
1679 402
AZD2014 346
diarrhoea 271
Statistically 138
highlighted 242
Third 282
TP53WT 496
MCM 496
BIW 276
schema 324
extrapolated 155
defines 345
Sarcomas 183
Actionable 273
VHIO 253
scribed 273
FGFRmut 372
ClinBen 372
unresponsive 237
overcoming 322
heavily-pretreated 366
onwards 276
CsA 496
modulator 275
inactivating 273
I-IV 162
imum 324
treatment-refractory 314
fourth 18
replaced 283
de-escalated 335
Tyrosine 469
tubes 96
quantitation 96
enoblituzumab 234
C6 276
BB 368
Aung 314
Naing 314
desirable 207
XMT-1522 234
QTc 272
circulation 369
EBP-a 275
Nintedanib 469
Nin 346
SM88 349
ascending 323
CDK9 467
X. 415
Transl 105
modular 242
recognizing 238
lymphodepleting 67
CPI-444 334
TGF-b 275
arginase 467
double-refractory 153
BORR 333
alters 322
Interaction 313
manifestations 390
eQTLs 111
IL10 299
thalami 34
NCT01044069 296
preceded 18
mitigation 484
autopsy 380
interleukin-2 321
Locke 153
29.5% 48
Integrative 56
PF-8600 38
gradual 223
pSTAT3 32
rs3212986 402
Jul 350
62.5% 152
predictions 235
PROG 22
chromatography 268
rho 200
Gaithersburg 470
origins 237
CART-133 334
CD137 32
ARG1 361
MCPyV-specific 32
multi-site 242
Anti-PD-1 373
TCRb 316
MHCI 32
Jiaotong 282
LDC 67
1.60 135
3.68 135
H1128-IL12 32
AP-HP 290
Therapies 290
Trametinib 496
90.9% 223
Lifehouse 183
sensitization 5
augmented 267
anti-PD1s 194
aNSCLC 194
C-index 430
Area 353
biopsied 380
subQ 32
KN158 333
DILI 272
adjacent 399
Crohn 316
tected 182
CD16 473
undetermined 331
curative-intent 244
BO-112 467
transplanted 128
NCT02009449 472
AE37 314
intradermal 67
TCRs 321
intraperitoneally 67
Roswell 107
myxoid 110
MRCLS 436
Cheson 329
mycosis 153
fungoides 153
jects 194
MEDI0562 234
Lesokhin 368
coordinated 213
rules 325
contingent 461
BRAF-mutated 184
TCID50 276
modulate 238
pM 419
CSF1 322
ALKS 234
4230 234
PGV001 234
Andre 169
mITT 188
41.3 51
randomizing 457
472 451
32.9 412
2.50 135
HiVitD 425
LowVitD 425
feedback 207
VIC 426
Minimum 450
liver-specific 389
K-ras 447
KRK 447
31.9 51
22.3 412
PETACC-8 323
43.2% 405
Pompidou 290
CAPOX 135
Ji 282
Won 282
Walter 282
MDACC 455
cessful 22
Saint 290
Antoine 290
Effective 229
Assessing 292
0.097 313
0.051 313
ARCAD 447
Lausanne 169
Short-term 435
ANG-2 112
fistula 459
18.9% 459
Treatments 447
Oxaliplatin 283
proficient 312
59.5 277
disturbances 61
LC3 419
years-old 447
Result 279
LV5FU2 283
Universitaire 169
folinic 283
37.1% 478
Perioperative 428
tinuous 439
Diane 226
0.064 389
toneal 381
69.5% 493
Improvement 61
2.85 135
2.91 135
2.57 135
survive 287
obser 43
27.7 412
Upfront 302
Rest 286
mediators 203
organoids 419
indicative 211
cGy 335
virtually 182
on-going 327
Oxa 98
Nodal 1
29.8 51
nonelderly 201
57.3% 405
FPKM 345
HOX 361
FACT 295
2.32 135
602 191
88.2% 359
496 397
2.10 135
38.5 51
27.1 51
mesorectal 335
ccfDNA 7
G12V 7
RAP 137
unbiased 37
1.82 135
2.92 135
2.47 135
52.9 277
SACURA 54
c-index 430
Hematological 26
fr 400
30.0% 478
triggering 238
tology 27
T-lymphocyte 373
mediator 275
nodules 34
VI 152
88.6% 405
KEYNOTE-059 423
N0-1 54
Zubrod 92
ESC 333
087 496
esophagitis 26
merit 33
Diagnostics 22
platinum-containing 423
yDFS 137
Oakland 107
Barr 56
aNon-CRC 474
CCNE1 7
M1a 54
calibration 430
Ian 466
Q6W 150
hyperthermic 383
pT2 431
PW-Post 382
CDDP 35
MMC 283
pStage 6
Klinik 384
CAPP-Seq 374
quantitated 96
two-sample 341
40.0% 405
AAs 75
SqCC 187
Mature 358
in-situ 434
Magnitude 46
remainder 173
Arm2 405
catumaxomab 176
HDGC 244
FPA144 38
Pritzker 107
62.3 277
nabPAC 440
reject 325
VEGF-C 458
Commonly 343
cramps 61
28.8% 1
Stereotactic 400
3.55 215
Cox-proportional 217
TMBI 7
munotherapy 82
ANCOVA 266
CLARINET 355
sc 67
OLE 355
NETest 458
mmol 300
serotonin 41
antagonists 477
Ga-OPS202 477
614 218
nabP 440
interrogation 109
Clavien 359
ago 244
Medi 470
tail 495
renders 322
sectable 423
SX 54
36.9% 152
underlie 315
RevGA 491
York-Presbyterian 230
long-lasting 207
INCB054828 496
written 219
Berlin 169
Wakayama 282
Sci 105
allocation 487
multi-agent 79
mutagenesis 237
KEYNOTE-045 340
lowered 269
Bernard 470
SU 141
Rini 448
2.31 135
R-P 492
36.5 412
extremely 416
meningitis 272
CRGA 273
melphalan 87
Beyer 188
salvaged 478
19.6% 405
Organization 295
EQ-5D-3L 138
progressions 82
SCBC 316
non-muscle 352
Urology 27
Bladder 348
S310F 7
THP 352
035 17
Carbo 428
Effectiveness 12
Moreau 352
cisplatinum 335
specialty 160
LG 307
censoring 359
Ifosfamide 283
schemes 308
69.2 277
IC95 412
Rome 169
triglycerides 271
METEOR 448
Nephrectomy 348
Strikingly 299
down-regulation 275
Select 293
WE 328
comparator 46
Natural 171
orphan 242
ANZUP 453
tivozanib 58
30.7% 438
57.7% 173
androgens 497
lyase 207
CTC0 303
unavailable 37
CRPC-Adeno 380
413 218
CARB 379
obstruction 99
intergroup 384
consolidative 281
52.4% 359
Janssen 27
2.79 135
opioid 138
life-extending 17
stringent 152
labs 128
MoCA 131
ARA 465
HSD3B1 497
PCWG2 14
EC1169 445
Jorge 63
Enzalutamide 497
PAP 32
CD107a 32
IRP 431
54.2% 1
BCR-free 135
ARlow 345
ARhigh 345
PSMA-avid 380
comprehensively 249
r2 361
conformal 335
LNM 182
Taxane 464
642 218
AHR 135
hypogonadal 488
pt-reported 206
MEDI3726 349
bloods 394
commenced 394
virus-associated 340
restoring 373
29.2 277
813 429
debulked 35
Confidence 135
problematic 46
nance 346
Supportive 158
AGO-OVAR 169
post-OP 141
END 433
GTV 335
preserve 195
HDAC 314
Histological 424
BRCA1-like 483
Moore 353
ICON 427
topotecan 164
d10 170
interference 61
mediating 203
BENIGNG 170
cl 433
Tax 35
fields 55
INSPIRE 375
persist 74
carcinosarcoma 424
comor 194
mEC 496
egies 195
curettage 449
p16-positive 405
involve 195
PROC 346
wPxl 346
poster 266
subclinical 161
oro 20
giant 183
intensified 335
assumption 265
NCT02105636 340
assumptions 46
beneficiaries 335
Mono 348
Endothelial 263
prescriptions 274
HPV-detect 228
PRO-CTCAE 138
feeding 266
tongue 20
module 61
DQB1 189
HPV2 434
transoral 335
ECE 54
Lugol 6
CRT75 478
HNSCCa 434
E2399 266
VHNSS 266
69.3 277
assisted 160
nanoparticles 465
SGC 229
RIFTOS 298
MyPathway 237
PI3K-AKT 275
anti-HBV 390
Edmonton 295
policies 213
Private 162
Spending 274
gaps 160
pharmaceutical 13
ASCOv1 200
ASCOv2 200
hypothetical 13
HSAs 13
AIAN 174
NHPI 174
chart-based 194
anti-myeloma 274
pre-ACA 17
recipients 274
Having 17
T-test 439
pct 17
KCR 265
voting 13
capita 46
organization 193
Discharge 102
interviewed 461
INEN 193
mix 46
intensivists 13
hospitalists 13
manufacturers 46
APMs 461
ten-year 110
Temporal 390
LIVESTRONG 162
GCI 160
LMICs 160
munity 160
non-curative 158
Included 161
Emily 470
Likert 461
passive 266
weekday 359
PAMs 210
PAM 210
IPCR 158
CEASE 13
emetogenic 41
DNR 158
Form 295
interviews 461
OS-derived 37
VFs 46
UCSD 27
BMT 27
MC1 7
CMC 7
ASXL1 236
HR-MDS 63
NCT01207440 254
CLAD 236
LDAC 236
Complex 7
Clad 19
SCA 487
T-ALL 316
pracinostat 236
ELN 64
IIT 236
DASISION 254
Telomere 171
Nail 295
Ruxolitinib 64
BCL-2 469
spliceosome 241
Bendamustine 87
CRu 366
non-del 19
immunochemotherapy 281
xCHOP-14 19
Richter 153
autoHCT 24
tocilizumab 272
cough 26
b-cell 153
Pomalidomide 87
GS-4059 496
ORR4 387
ven 19
Cardiovascular 390
AFIB 272
cHL 369
suspension 49
extranodal 281
CD79B 62
LGL 473
Salvage 281
LAC 359
NKTL 237
JAK-STAT 273
20.3% 359
DHL 62
Myc 5
Ommaya 18
RCVP 281
ENTO 469
BTKi 153
DTRM-12 496
DTRM-555 496
Carfilzomib 87
bortez 87
Torino 476
VMP 411
Tuebingen 476
up-front 87
heteroclitic 311
Heart 220
Connect 331
SPMs 272
NMA 12
Stat 200
ASPIRE 118
ENDEAVOR 352
autonomic 61
CWP291 496
non-small-cell 282
GGH 282
ETOP 466
myasthenia 459
gravis 459
SBM 54
Typical 45
CxRT 307
gITH 182
PL 54
ASS1-deficient 35
TRAP 35
ASS1 120
ALCHEMIST 242
METD14 279
CIT 398
T790M-positive 278
cFAS 379
evolutionary 374
ACS 53
EGFRmutations 82
Anlotinib 58
CRZ-resistant 58
cORR 333
ROS1-E32 173
OSI 278
636 397
psycho-oncological 195
BREAK-2 404
601 185
ARAs 465
resuming 421
TLR 322
Resiquimod 322
BCCs 373
CC-486 131
agitated 159
RASS 266
new-onset 102
CRCI 123
exercisers 203
avoidant 61
anti-dementia 274
CwC-1 17
CwC-2 17
age-based 298
Activin 364
Myostatin 364
SMART-3RP 61
ETT 258
Survivorship 461
MWT 138
BIS 298
OXN 61
sciatic 34
CACI 97
coherence 61
HRV-B 266
HLA-DQB1 203
MT-CO2 203
SOAPP-14 393
OTT 266
pLGG 493
HER2-CAR 67
Larotrectinib 469
IFS 237
PedsQL 138
VAIA 405
hu14 387
GANET 67
sheath 124
SDS 300
MCS 123
Vitality 123
PBTS 298
mechanical 34
Bordeaux 290
trunk 227
CUM 220
WP 425
dimensional 481
SSD 288
LRFS 1
Tazemetostat 273
PDGFD 430
VAC 281
RPS 399
CAML 208
mGIST 413
BLC 343
CEUS 209
pre-chemo 458
OPN 112
UPR 369
Rv1 419
DLC1 369
ABCG2 185
TOP-1 185
TC1 73
E5 51
UtCa 343
HER3-EGFR 361
necroptosis 97
MLKL 97
